Seules les publications les plus récentes sont présentées – Pour voir plus de publications aller à la page de recherche : toutes les publications
Only the most recent publications are displayed – to see more, go to the search page : all publications
1368488
tuberculosis
1
heidelberg-university-faculty-of-medicine
50
date
desc
1
245
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A200%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22ULGLVJW6%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Godefroy%20et%20al.%22%2C%22parsedDate%22%3A%222024-07-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGodefroy%2C%20N.%2C%20Monsel%2C%20G.%2C%20Jaur%26%23xE9%3Bguiberry%2C%20S.%2C%20Henry%2C%20B.%2C%20V%26%23xE9%3Bziris%2C%20N.%2C%20Aubry%2C%20A.%2C%20Robert%2C%20J.%2C%20Jachym%2C%20M.%2C%20Caumes%2C%20E.%20and%20Pourcher%2C%20V.%20%282024%29.%20%3Cb%3ELessons%20learned%20from%20treating%20drug-resistant%20TB%20and%20how%20to%20apply%20these%20to%20drug-susceptible%20TB%3C%5C%2Fb%3E.%20int%20j%20tuberc%20lung%20dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%20357%26%23x2013%3B359%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.23.0548%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.23.0548%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lessons%20learned%20from%20treating%20drug-resistant%20TB%20and%20how%20to%20apply%20these%20to%20drug-susceptible%20TB%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Godefroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Monsel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Jaur%5Cu00e9guiberry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22V%5Cu00e9ziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Pourcher%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-07-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.23.0548%22%2C%22ISSN%22%3A%221027-3719%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ingentaconnect.com%5C%2Fcontent%5C%2F10.5588%5C%2Fijtld.23.0548%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-07-17T14%3A19%3A59Z%22%7D%7D%2C%7B%22key%22%3A%222HSDN9QD%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Veziris%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-19%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVeziris%2C%20N.%2C%20Aubry%2C%20A.%2C%20Bonnet%2C%20I.%2C%20Petersen%2C%20T.%2C%20Poignon%2C%20C.%2C%20Gyd%26%23xE9%3B%2C%20E.%2C%20Guglielmetti%2C%20L.%20and%20Robert%2C%20J.%20%282024%29.%20%3Cb%3EActualit%26%23xE9%3Bs%20sur%20la%20tuberculose%20%26%23xE0%3B%20bacilles%20multir%26%23xE9%3Bsistants%20aux%20antibiotiques%20et%20ses%20nouveaux%20traitements%3C%5C%2Fb%3E.%20Bull%20%26%23xC9%3Bpid%20Hebdo%20127%26%23x2013%3B131%2C%20URL%3A%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fbeh.santepubliquefrance.fr%5C%2Fbeh%5C%2F2024%5C%2F6-7%5C%2F2024_6-7_4.html%27%3Ehttp%3A%5C%2F%5C%2Fbeh.santepubliquefrance.fr%5C%2Fbeh%5C%2F2024%5C%2F6-7%5C%2F2024_6-7_4.html%3C%5C%2Fa%3E%20%5BAccessed%20March%202024%5D.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Actualit%5Cu00e9s%20sur%20la%20tuberculose%20%5Cu00e0%20bacilles%20multir%5Cu00e9sistants%20aux%20antibiotiques%20et%20ses%20nouveaux%20traitements%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Petersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Poignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Gyd%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-03-19%22%2C%22language%22%3A%22French%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fbeh.santepubliquefrance.fr%5C%2Fbeh%5C%2F2024%5C%2F6-7%5C%2F2024_6-7_4.html%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-03-19T17%3A03%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22VNSB8L8Y%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Friesen%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFriesen%2C%20I.%2C%20Saluzzo%2C%20F.%2C%20Groenheit%2C%20R.%2C%20Aubry%2C%20A.%2C%20Anthony%2C%20R.%2C%20Niemann%2C%20S.%2C%20Mathys%2C%20V.%2C%20Cirillo%2C%20D.%20M.%2C%20Indra%2C%20A.%2C%20Mathys%2C%20V.%2C%20Atanasova%2C%20Y.%2C%20Obrovac%2C%20M.%2C%20%26%23x17D%3Bmak%2C%20L.%2C%20Pieridou%2C%20D.%2C%20Dvo%26%23x159%3B%26%23xE1%3Bkov%2C%20V.%2C%20Troels%20Lilleb%26%23xE6%3Bk%2C%20Kummik%2C%20T.%2C%20Klaos%2C%20K.%2C%20Soini%2C%20H.%2C%20Haanper%26%23xE4%3B-Heikkinen%2C%20M.%2C%20Mentula%2C%20S.%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%2C%20R.%2C%20Cambau%2C%20E.%2C%20Niemann%2C%20S.%2C%20Panayotis%2C%20I.%2C%20Papaventsis%2C%20D.%2C%20Bakos%2C%20%26%23xC1%3B.%2C%20Sz%26%23xE9%3Bl%2C%20V.%2C%20L%26%23x151%3Brinczi%2C%20L.%20K.%2C%20Fitzgibbon%2C%20M.%2C%20Boyle%2C%20B.%2C%20Cirillo%2C%20D.%20M.%2C%20Giannoni%2C%20F.%2C%20Pole%2C%20I.%2C%20Norvai%26%23x161%3Ba%2C%20I.%2C%20Vasiliauskaite%2C%20L.%2C%20Perrin%2C%20M.%2C%20Deguara%2C%20C.%2C%20Anthony%2C%20R.%2C%20Mengshoel%2C%20A.%20T.%2C%20Augustynowicz-Kope%26%23x107%3B%2C%20E.%2C%20Macedo%2C%20R.%2C%20Coriu%2C%20R.%20M.%2C%20Porvaznik%2C%20I.%2C%20Klemen%2C%20%26%23x160%3B.%2C%20Herrera-Le%26%23xF3%3Bn%2C%20L.%2C%20Groenheit%2C%20R.%20and%20Werngren%2C%20J.%20%282024%29.%20%3Cb%3ERe%3A%20%26%23x201C%3BAvailability%20of%20drugs%20and%20resistance%20testing%20for%20BPaLM%20regimen%20for%20rifampicin-resistant%20tuberculosis%20in%20Europe%26%23x201D%3B%20by%20Lange%20et%20al.%3C%5C%2Fb%3E%20Clinical%20Microbiology%20and%20Infection%20S1198743X24002775%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2024.06.001%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2024.06.001%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Re%3A%20%5Cu2018Availability%20of%20drugs%20and%20resistance%20testing%20for%20BPaLM%20regimen%20for%20rifampicin-resistant%20tuberculosis%20in%20Europe%5Cu2019%20by%20Lange%20et%20al.%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Inna%22%2C%22lastName%22%3A%22Friesen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Saluzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramona%22%2C%22lastName%22%3A%22Groenheit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Anthony%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Mathys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20Maria%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Indra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Mathys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuliana%22%2C%22lastName%22%3A%22Atanasova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mihaela%22%2C%22lastName%22%3A%22Obrovac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ljiljiana%22%2C%22lastName%22%3A%22%5Cu017dmak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Despo%22%2C%22lastName%22%3A%22Pieridou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu011bra%22%2C%22lastName%22%3A%22Dvo%5Cu0159%5Cu00e1kov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Troels%20Lilleb%5Cu00e6k%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiina%22%2C%22lastName%22%3A%22Kummik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kadri%22%2C%22lastName%22%3A%22Klaos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanna%22%2C%22lastName%22%3A%22Soini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marjo%22%2C%22lastName%22%3A%22Haanper%5Cu00e4-Heikkinen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silja%22%2C%22lastName%22%3A%22Mentula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioannidis%22%2C%22lastName%22%3A%22Panayotis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitrios%22%2C%22lastName%22%3A%22Papaventsis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1gnes%22%2C%22lastName%22%3A%22Bakos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vikt%5Cu00f3ria%22%2C%22lastName%22%3A%22Sz%5Cu00e9l%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lilla%20Katalin%22%2C%22lastName%22%3A%22L%5Cu0151rinczi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaret%22%2C%22lastName%22%3A%22Fitzgibbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Breida%22%2C%22lastName%22%3A%22Boyle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20Maria%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Federico%22%2C%22lastName%22%3A%22Giannoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilva%22%2C%22lastName%22%3A%22Pole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Inga%22%2C%22lastName%22%3A%22Norvai%5Cu0161a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laima%22%2C%22lastName%22%3A%22Vasiliauskaite%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Perrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catriona%22%2C%22lastName%22%3A%22Deguara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Anthony%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20Torunn%22%2C%22lastName%22%3A%22Mengshoel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ewa%22%2C%22lastName%22%3A%22Augustynowicz-Kope%5Cu0107%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rita%22%2C%22lastName%22%3A%22Macedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxana%20Mihaela%22%2C%22lastName%22%3A%22Coriu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igor%22%2C%22lastName%22%3A%22Porvaznik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu0160pela%22%2C%22lastName%22%3A%22Klemen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Herrera-Le%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramona%22%2C%22lastName%22%3A%22Groenheit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jim%22%2C%22lastName%22%3A%22Werngren%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%226%5C%2F2024%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2024.06.001%22%2C%22ISSN%22%3A%221198743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1198743X24002775%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-07-17T14%3A23%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22TGPHGG7Y%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Baulard%2C%20A.%2C%20Aubry%2C%20A.%20and%20Veziris%2C%20N.%20%282024%29.%20%3Cb%3EOptimizing%20the%20use%20of%20current%20antituberculosis%20drugs%20to%20overcome%20drug%20resistance%20in%20Mycobacterium%20tuberculosis%3C%5C%2Fb%3E.%20Infectious%20Diseases%20Now%20%3Ci%3E54%3C%5C%2Fi%3E%2C%20104807%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.idnow.2023.104807%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.idnow.2023.104807%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Optimizing%20the%20use%20of%20current%20antituberculosis%20drugs%20to%20overcome%20drug%20resistance%20in%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Baulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2202%5C%2F2024%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.idnow.2023.104807%22%2C%22ISSN%22%3A%2226669919%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS2666991923001690%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-11-13T09%3A44%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22V2XSRDIF%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Guglielmetti%2C%20L.%2C%20Robert%2C%20J.%2C%20Aubry%2C%20A.%20and%20Veziris%2C%20N.%20%282024%29.%20%3Cb%3EAvanc%26%23xE9%3Bes%20dans%20l%26%23x2019%3Bantibioth%26%23xE9%3Brapie%20de%20la%20tuberculose%3C%5C%2Fb%3E.%20Rev%20Prat%20%3Ci%3E74%3C%5C%2Fi%3E%2C%20239%26%23x2013%3B244.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Avanc%5Cu00e9es%20dans%20l%5Cu2019antibioth%5Cu00e9rapie%20de%20la%20tuberculose%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-03-19T17%3A06%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22WVC2IXYE%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Campbell%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECampbell%2C%20J.%20R.%2C%20Brode%2C%20S.%20K.%2C%20Barry%2C%20P.%2C%20Bastos%2C%20M.%20L.%2C%20Bonnet%2C%20M.%2C%20Guglielmetti%2C%20L.%2C%20Kempker%2C%20R.%2C%20Klimuk%2C%20D.%2C%20Labor%26%23xED%3Bn%2C%20R.%20L.%2C%20Milanov%2C%20V.%2C%20Singla%2C%20R.%2C%20Skrahina%2C%20A.%2C%20Trajman%2C%20A.%2C%20Van%20Der%20Werf%2C%20T.%20S.%2C%20Viiklepp%2C%20P.%20and%20Menzies%2C%20D.%20%282023%29.%20%3Cb%3EAssociation%20of%20indicators%20of%20extensive%20disease%20and%20rifampin-resistant%20tuberculosis%20treatment%20outcomes%3A%20an%20individual%20participant%20data%20meta-analysis%3C%5C%2Fb%3E.%20Thorax%20thorax-2023-220249%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fthorax-2023-220249%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fthorax-2023-220249%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20indicators%20of%20extensive%20disease%20and%20rifampin-resistant%20tuberculosis%20treatment%20outcomes%3A%20an%20individual%20participant%20data%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathon%20R%22%2C%22lastName%22%3A%22Campbell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20K%22%2C%22lastName%22%3A%22Brode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pennan%22%2C%22lastName%22%3A%22Barry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mayara%20Lisboa%22%2C%22lastName%22%3A%22Bastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryline%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Russell%22%2C%22lastName%22%3A%22Kempker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dzmitry%22%2C%22lastName%22%3A%22Klimuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%20Laniado%22%2C%22lastName%22%3A%22Labor%5Cu00edn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladimir%22%2C%22lastName%22%3A%22Milanov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rupak%22%2C%22lastName%22%3A%22Singla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anete%22%2C%22lastName%22%3A%22Trajman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tjip%20S%22%2C%22lastName%22%3A%22Van%20Der%20Werf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Piret%22%2C%22lastName%22%3A%22Viiklepp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dick%22%2C%22lastName%22%3A%22Menzies%22%7D%5D%2C%22abstractNote%22%3A%22Background%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Indicators%20of%20extensive%20disease%5Cu2014acid%20fast%20bacilli%20%28AFB%29%20smear%20positivity%20and%20lung%20cavitation%5Cu2014have%20been%20inconsistently%20associated%20with%20clinical%20rifampin-resistant%5C%2Fmultidrug-resistant%20tuberculosis%20%28RR%5C%2FMDR-TB%29%20outcomes.%20We%20evaluated%20the%20association%20of%20these%20indicators%20with%20end-of-treatment%20outcomes.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20did%20an%20individual%20participant%20data%20meta-analysis%20of%20people%20treated%20for%20RR%5C%2FMDR-TB%20with%20longer%20regimens%20with%20documented%20AFB%20smear%20and%20chest%20radiography%20findings.%20We%20compared%20people%20AFB%20smear-negative%20without%20cavities%20to%20people%3A%20%281%29%20smear-negative%20with%20lung%20cavities%3B%20%282%29%20smear-positive%20without%20lung%20cavities%20and%20%283%29%20AFB%20smear-positive%20with%20lung%20cavities.%20Using%20multivariable%20logistic%20regression%20accounting%20for%20demographic%2C%20treatment%20and%20clinical%20factors%2C%20we%20calculated%20adjusted%20ORs%20%28aOR%29%20for%20any%20unfavourable%20outcome%20%28death%2C%20lost%20to%20follow-up%2C%20failure%5C%2Frecurrence%29%2C%20and%20mortality%20and%20treatment%20failure%5C%2Frecurrence%20alone.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20included%205596%20participants%3B%20included%20participants%20significantly%20differed%20from%20excluded%20participants.%20Overall%2C%20774%20%2813.8%25%29%20were%20AFB%20smear-negative%20without%20cavities%2C%20647%20%2811.6%25%29%20only%20had%20cavities%2C%201424%20%2825.4%25%29%20were%20AFB%20smear-positive%20alone%20and%202751%20%2849.2%25%29%20were%20AFB%20smear-positive%20with%20cavities.%20The%20median%20age%20was%2037%20years%20%28IQR%3A%2028%5Cu201347%29%2C%203580%20%2864%25%29%20were%20male%20and%20686%20%2812.5%25%29%20had%20HIV.%20Compared%20with%20participants%20AFB%20smear-negative%20without%20cavities%2C%20aOR%20%2895%25%20CI%29%20for%20any%20unfavourable%20outcome%20was%201.0%20%280.8%20to%201.4%29%20for%20participants%20smear-negative%20with%20lung%20cavities%2C%201.2%20%280.9%20to%201.5%29%20if%20smear-positive%20without%20cavities%20and%201.6%20%281.3%20to%202.0%29%20if%20AFB%20smear-positive%20with%20lung%20cavities.%20Odds%20were%20only%20significantly%20increased%20for%20mortality%20%281.5%2C%2095%25%20CI%201.1%20to%202.1%29%20and%20failure%5C%2Frecurrence%20%282.2%2C%2095%25%20CI%201.5%20to%203.3%29%20among%20participants%20AFB%20smear-positive%20with%20lung%20cavities.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Only%20the%20combination%20of%20AFB%20smear-positivity%20and%20lung%20cavitation%20was%20associated%20with%20unfavourable%20outcomes%2C%20suggesting%20they%20may%20benefit%20from%20stronger%20regimens.%22%2C%22date%22%3A%222023-12-22%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fthorax-2023-220249%22%2C%22ISSN%22%3A%220040-6376%2C%201468-3296%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fthorax.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fthorax-2023-220249%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-12-31T15%3A24%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22AYT74SVL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Du%20Cros%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDu%20Cros%2C%20P.%2C%20Greig%2C%20J.%2C%20Alffenaar%2C%20J.-W.%20C.%2C%20Cross%2C%20G.%20B.%2C%20Cousins%2C%20C.%2C%20Berry%2C%20C.%2C%20Khan%2C%20U.%2C%20Phillips%2C%20P.%20P.%20J.%2C%20Vel%26%23xE1%3Bsquez%2C%20G.%20E.%2C%20Furin%2C%20J.%2C%20Spigelman%2C%20M.%2C%20Denholm%2C%20J.%20T.%2C%20Thi%2C%20S.%20S.%2C%20Tiberi%2C%20S.%2C%20Huang%2C%20G.%20K.%20L.%2C%20Marks%2C%20G.%20B.%2C%20Turkova%2C%20A.%2C%20Guglielmetti%2C%20L.%2C%20Chew%2C%20K.%20L.%2C%20Nguyen%2C%20H.%20T.%2C%20Ong%2C%20C.%20W.%20M.%2C%20Brigden%2C%20G.%2C%20Singh%2C%20K.%20P.%2C%20Motta%2C%20I.%2C%20Lange%2C%20C.%2C%20Seddon%2C%20J.%20A.%2C%20Nyang%26%23x2019%3Bwa%2C%20B.-T.%2C%20Maug%2C%20A.%20K.%20J.%2C%20Gler%2C%20M.%20T.%2C%20Dooley%2C%20K.%20E.%2C%20Quelapio%2C%20M.%2C%20Tsogt%2C%20B.%2C%20Menzies%2C%20D.%2C%20Cox%2C%20V.%2C%20Upton%2C%20C.%20M.%2C%20Skrahina%2C%20A.%2C%20McKenna%2C%20L.%2C%20Horsburgh%2C%20C.%20R.%2C%20Dheda%2C%20K.%20and%20Marais%2C%20B.%20J.%20%282023%29.%20%3Cb%3EStandards%20for%20clinical%20trials%20for%20treating%20TB%3C%5C%2Fb%3E.%20int%20j%20tuberc%20lung%20dis%20%3Ci%3E27%3C%5C%2Fi%3E%2C%20885%26%23x2013%3B898%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.23.0341%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.23.0341%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Standards%20for%20clinical%20trials%20for%20treating%20TB%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Du%20Cros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Greig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-W.%20C.%22%2C%22lastName%22%3A%22Alffenaar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20B.%22%2C%22lastName%22%3A%22Cross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cousins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Berry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20P.%20J.%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20E.%22%2C%22lastName%22%3A%22Vel%5Cu00e1squez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Furin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Spigelman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22Denholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20S.%22%2C%22lastName%22%3A%22Thi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20K.%20L.%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20B.%22%2C%22lastName%22%3A%22Marks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Turkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20L.%22%2C%22lastName%22%3A%22Chew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20T.%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%20M.%22%2C%22lastName%22%3A%22Ong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Brigden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20P.%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Motta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Seddon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B-T.%22%2C%22lastName%22%3A%22Nyang%5Cu2019wa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20K.%20J.%22%2C%22lastName%22%3A%22Maug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20T.%22%2C%22lastName%22%3A%22Gler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20E.%22%2C%22lastName%22%3A%22Dooley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Quelapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Tsogt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Upton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22McKenna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20R.%22%2C%22lastName%22%3A%22Horsburgh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20J.%22%2C%22lastName%22%3A%22Marais%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20value%2C%20speed%20of%20completion%20and%20robustness%20of%20the%20evidence%20generated%20by%20TB%20treatment%20trials%20could%20be%20improved%20by%20implementing%20standards%20for%20best%20practice.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20METHODS%3A%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%20global%20panel%20of%20experts%20participated%20in%20a%20Delphi%20process%2C%20using%20a%207-point%20Likert%20scale%20%5Cn%20to%20score%20and%20revise%20draft%20standards%20until%20consensus%20was%20reached.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20RESULTS%3A%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Eleven%20standards%20were%20defined%3A%20Standard%201%2C%20high%20quality%20data%20on%20TB%20regimens%20are%20essential%20to%20inform%20clinical%20and%20programmatic%20management%3B%20Standard%202%2C%20the%20research%20questions%20addressed%20by%20TB%20trials%20should%20be%20%5Cn%20relevant%20to%20affected%20communities%2C%20who%20should%20be%20included%20in%20all%20trial%20stages%3B%20Standard%203%2C%20trials%20should%20make%20every%20effort%20to%20be%20as%20inclusive%20as%20possible%3B%20Standard%204%2C%20the%20most%20efficient%20trial%20designs%20should%20be%20considered%20to%20improve%20the%20evidence%20base%20as%20quickly%20and%20cost%20effectively%20as%20possible%2C%20%5Cn%20without%20compromising%20quality%3B%20Standard%205%2C%20trial%20governance%20should%20be%20in%20line%20with%20accepted%20good%20clinical%20practice%3B%20Standard%206%2C%20trials%20should%20investigate%20and%20report%20strategies%20that%20promote%20optimal%20engagement%20in%20care%3B%20Standard%207%2C%20where%20possible%2C%20TB%20trials%20should%20include%20pharmacokinetic%20and%20pharmacodynamic%20%5Cn%20components%3B%20Standard%208%2C%20outcomes%20should%20include%20frequency%20of%20disease%20recurrence%20and%20post-treatment%20sequelae%3B%20Standard%209%2C%20TB%20trials%20should%20aim%20to%20harmonise%20key%20outcomes%20and%20data%20structures%20across%20studies%3B%20Standard%2010%2C%20TB%20trials%20should%20include%20biobanking%3B%20Standard%2011%2C%20treatment%20trials%20should%20%5Cn%20invest%20in%20capacity%20strengthening%20of%20local%20trial%20and%20TB%20programme%20staff.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20CONCLUSION%3A%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20These%20standards%20should%20improve%20the%20efficiency%20and%20effectiveness%20of%20evidence%20generation%2C%20as%20well%20as%20the%20translation%20of%20research%20into%20policy%20and%20practice.%22%2C%22date%22%3A%222023-12-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.23.0341%22%2C%22ISSN%22%3A%221027-3719%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ingentaconnect.com%5C%2Fcontent%5C%2F10.5588%5C%2Fijtld.23.0341%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-12-31T15%3A25%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22NLTQM49X%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Patil%20et%20al.%22%2C%22parsedDate%22%3A%222023-11-30%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPatil%2C%20S.%20B.%2C%20Tamirat%2C%20M.%2C%20Khazhidinov%2C%20K.%2C%20Ardizzoni%2C%20E.%2C%20Atger%2C%20M.%2C%20Austin%2C%20A.%2C%20Baudin%2C%20E.%2C%20Bekhit%2C%20M.%2C%20Bektasov%2C%20S.%2C%20Berikova%2C%20E.%2C%20Bonnet%2C%20M.%2C%20Caboclo%2C%20R.%2C%20Chaudhry%2C%20M.%2C%20Chavan%2C%20V.%2C%20Cloez%2C%20S.%2C%20Coit%2C%20J.%2C%20Coutisson%2C%20S.%2C%20Dakenova%2C%20Z.%2C%20De%20Jong%2C%20B.%20C.%2C%20Delifer%2C%20C.%2C%20Demaisons%2C%20S.%2C%20Do%2C%20J.%20M.%2C%20Dos%20Santos%20Tozzi%2C%20D.%2C%20Ducher%2C%20V.%2C%20Ferlazzo%2C%20G.%2C%20Gouillou%2C%20M.%2C%20Khan%2C%20U.%2C%20Kunda%2C%20M.%2C%20Lachenal%2C%20N.%2C%20LaHood%2C%20A.%20N.%2C%20Lecca%2C%20L.%2C%20Mazmanian%2C%20M.%2C%20McIlleron%2C%20H.%2C%20Moreau%2C%20M.%2C%20Moschioni%2C%20M.%2C%20Nahid%2C%20P.%2C%20Osso%2C%20E.%2C%20Oyewusi%2C%20L.%2C%20Panda%2C%20S.%2C%20P%26%23xE2%3Bquet%2C%20A.%2C%20Thuong%20Huu%2C%20P.%2C%20Pichon%2C%20L.%2C%20Rich%2C%20M.%20L.%2C%20Rupasinghe%2C%20P.%2C%20Salahuddin%2C%20N.%2C%20Sanchez%20Garavito%2C%20E.%2C%20Seung%2C%20K.%20J.%2C%20Vel%26%23xE1%3Bsquez%2C%20G.%20E.%2C%20Vallet%2C%20M.%2C%20Varaine%2C%20F.%2C%20Yuya-Septoh%2C%20F.%20J.%2C%20Mitnick%2C%20C.%20D.%20and%20Guglielmetti%2C%20L.%20%282023%29.%20%3Cb%3EEvaluating%20newly%20approved%20drugs%20in%20combination%20regimens%20for%20multidrug-resistant%20tuberculosis%20with%20fluoroquinolone%20resistance%20%28endTB-Q%29%3A%20study%20protocol%20for%20a%20multi-country%20randomized%20controlled%20trial%3C%5C%2Fb%3E.%20Trials%20%3Ci%3E24%3C%5C%2Fi%3E%2C%20773%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-023-07701-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-023-07701-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluating%20newly%20approved%20drugs%20in%20combination%20regimens%20for%20multidrug-resistant%20tuberculosis%20with%20fluoroquinolone%20resistance%20%28endTB-Q%29%3A%20study%20protocol%20for%20a%20multi-country%20randomized%20controlled%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20B.%22%2C%22lastName%22%3A%22Patil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tamirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Khazhidinov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Ardizzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Atger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Austin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Baudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bekhit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bektasov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Berikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Caboclo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Chaudhry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Chavan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Cloez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Coit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Coutisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Dakenova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20C.%22%2C%22lastName%22%3A%22De%20Jong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Delifer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Demaisons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Dos%20Santos%20Tozzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Ducher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Ferlazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Gouillou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kunda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Lachenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20N.%22%2C%22lastName%22%3A%22LaHood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Lecca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mazmanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22McIlleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Moschioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Nahid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Osso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Oyewusi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Panda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22P%5Cu00e2quet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Thuong%20Huu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Pichon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Rich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Salahuddin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Sanchez%20Garavito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20J.%22%2C%22lastName%22%3A%22Seung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20E.%22%2C%22lastName%22%3A%22Vel%5Cu00e1squez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Vallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Varaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20J.%22%2C%22lastName%22%3A%22Yuya-Septoh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Mitnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Background%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Treatment%20for%20fluoroquinolone-resistant%20multidrug-resistant%5C%2Frifampicin-resistant%20tuberculosis%20%28pre-XDR%20TB%29%20often%20lasts%20longer%20than%20treatment%20for%20less%20resistant%20strains%2C%20yields%20worse%20efficacy%20results%2C%20and%20causes%20substantial%20toxicity.%20The%20newer%20anti-tuberculosis%20drugs%2C%20bedaquiline%20and%20delamanid%2C%20and%20repurposed%20drugs%20clofazimine%20and%20linezolid%2C%20show%20great%20promise%20for%20combination%20in%20shorter%2C%20less-toxic%2C%20and%20effective%20regimens.%20To%20date%2C%20there%20has%20been%20no%20randomized%2C%20internally%20and%20concurrently%20controlled%20trial%20of%20a%20shorter%2C%20all-oral%20regimen%20comprising%20these%20newer%20and%20repurposed%20drugs%20sufficiently%20powered%20to%20produce%20results%20for%20pre-XDR%20TB%20patients.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20endTB-Q%20is%20a%20phase%20III%2C%20multi-country%2C%20randomized%2C%20controlled%2C%20parallel%2C%20open-label%20clinical%20trial%20evaluating%20the%20efficacy%20and%20safety%20of%20a%20treatment%20strategy%20for%20patients%20with%20pre-XDR%20TB.%20Study%20participants%20are%20randomized%202%3A1%20to%20experimental%20or%20control%20arms%2C%20respectively.%20The%20experimental%20arm%20contains%20bedaquiline%2C%20linezolid%2C%20clofazimine%2C%20and%20delamanid.%20The%20control%20comprises%20the%20contemporaneous%20WHO%20standard%20of%20care%20for%20pre-XDR%20TB.%20Experimental%20arm%20duration%20is%20determined%20by%20a%20composite%20of%20smear%20microscopy%20and%20chest%20radiographic%20imaging%20at%20baseline%20and%20re-evaluated%20at%206%5Cu00a0months%20using%20sputum%20culture%20results%3A%20participants%20with%20less%20extensive%20disease%20receive%206%5Cu00a0months%20and%20participants%20with%20more%20extensive%20disease%20receive%209%5Cu00a0months%20of%20treatment.%20Randomization%20is%20stratified%20by%20country%20and%20by%20participant%20extent-of-TB-disease%20phenotype%20defined%20according%20to%20screening%5C%2Fbaseline%20characteristics.%20Study%20participation%20lasts%20up%20to%20104%5Cu00a0weeks%20post%20randomization.%20The%20primary%20objective%20is%20to%20assess%20whether%20the%20efficacy%20of%20experimental%20regimens%20at%2073%5Cu00a0weeks%20is%20non-inferior%20to%20that%20of%20the%20control.%20A%20sample%20size%20of%20324%20participants%20across%202%20arms%20affords%20at%20least%2080%25%20power%20to%20show%20the%20non-inferiority%2C%20with%20a%20one-sided%20alpha%20of%200.025%20and%20a%20non-inferiority%20margin%20of%2012%25%2C%20against%20the%20control%20in%20both%20modified%20intention-to-treat%20and%20per-protocol%20populations.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Discussion%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20internally%20controlled%20study%20of%20shortened%20treatment%20for%20pre-XDR%20TB%20will%20provide%20urgently%20needed%20data%20and%20evidence%20for%20clinical%20and%20policy%20decision-making%20around%20the%20treatment%20of%20pre-XDR%20TB%20with%20a%20four-drug%2C%20all-oral%2C%20shortened%20regimen.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Trial%20registration%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ClinicalTrials.Gov%20NCT03896685.%20Registered%20on%201%20April%202018%3B%20the%20record%20was%20last%20updated%20for%20study%20protocol%20version%204.3%20on%2017%20March%202023.%22%2C%22date%22%3A%222023-11-30%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13063-023-07701-6%22%2C%22ISSN%22%3A%221745-6215%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ftrialsjournal.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs13063-023-07701-6%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-12-31T15%3A25%3A49Z%22%7D%7D%2C%7B%22key%22%3A%229EZSBXQY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sahal%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESahal%2C%20M.%20R.%2C%20Senelle%2C%20G.%2C%20La%2C%20K.%2C%20Panda%2C%20T.%20W.%2C%20Taura%2C%20D.%20W.%2C%20Guyeux%2C%20C.%2C%20Cambau%2C%20E.%20and%20Sola%2C%20C.%20%282023%29.%20%3Cb%3EMycobacterium%20tuberculosis%20complex%20drug-resistance%2C%20phylogenetics%2C%20and%20evolution%20in%20Nigeria%3A%20Comparison%20with%20Ghana%20and%20Cameroon%3C%5C%2Fb%3E%20Ed.%20Rayner%2C%20S.%20PLoS%20Negl%20Trop%20Dis%20%3Ci%3E17%3C%5C%2Fi%3E%2C%20e0011619%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0011619%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0011619%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mycobacterium%20tuberculosis%20complex%20drug-resistance%2C%20phylogenetics%2C%20and%20evolution%20in%20Nigeria%3A%20Comparison%20with%20Ghana%20and%20Cameroon%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammed%20Rabiu%22%2C%22lastName%22%3A%22Sahal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetan%22%2C%22lastName%22%3A%22Senelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22La%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tukur%20Wada%22%2C%22lastName%22%3A%22Panda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dalha%20Wada%22%2C%22lastName%22%3A%22Taura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Guyeux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Sola%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Rayner%22%7D%5D%2C%22abstractNote%22%3A%22In%20this%20article%2C%20we%20provide%20an%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20in-depth%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20analysis%20on%20the%20drug-resistance%20phenotypic%20characteristics%20of%20a%20cohort%20of%20325%20tuberculosis%20and%20characterize%20by%20Whole%20Genome%20Sequencing%2024%20isolates%20from%20Nigeria%20belonging%20to%20L4%2C%20L5%20and%20L6.%20Our%20results%20suggest%20an%20alarming%20rate%20of%20drug-resistance%20of%20the%20L4.6.2.2%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Mycobacterium%20tuberculosis%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20complex%20%28MTBC%29%20lineage%20and%20a%20high%20diversity%20of%20L5.%20We%20compiled%20these%20new%20Sequence%20Read%20Archives%20%28SRAs%29%20to%20previously%20published%20ones%20from%20available%20Bioprojects%20run%20in%20Nigeria.%20We%20performed%20RAxML%20phylogenetic%20reconstructions%20of%20larger%20samples%20that%20include%20public%20NCBI%20SRAs%20from%20some%20neighboring%20countries%20%28Cameroon%2C%20Ghana%29.%20To%20confront%20phylogenetic%20reconstruction%20to%20metadata%2C%20we%20used%20a%20new%20proprietary%20database%20named%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20TB-Annotator%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20We%20show%20that%20L5%20genomes%20in%20Northern%20Nigeria%20belong%20to%20new%20clades%20as%20the%20ones%20described%20until%20now%20and%20allow%20an%20update%20of%20the%20taxonomy%20of%20L5.%20In%20addition%2C%20we%20describe%20the%20L4.6.2.2%20lineage%20in%20Nigeria%2C%20Cameroon%20and%20Ghana.%20We%20provide%20computations%20on%20the%20likely%20divergence%20time%20of%20L4.6.2.2%20and%20suggest%20a%20new%20hypothesis%20concerning%20its%20origin.%20Finally%20we%20provide%20a%20short%20overview%20on%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20M%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20bovis%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20diversity%20in%20Nigeria.%20This%20study%20constitutes%20a%20baseline%20knowledge%20on%20the%20global%20genomic%20diversity%2C%20phylogeography%20and%20phylodynamics%20of%20MTBC%20in%20Nigeria%2C%20as%20well%20as%20on%20the%20natural%20history%20of%20this%20largely%20ignored%20but%20densely%20populated%20country%20of%20Africa.%20These%20results%20highlight%20the%20need%20of%20sequencing%20additional%20MTBC%20genomes%20in%20Nigeria%20and%20more%20generally%20in%20West-Africa%2C%20both%20for%20public%20health%20and%20for%20academic%20reasons.%20The%20likelihood%20of%20replacement%20of%20L5-L6%20by%20L4.6.2.2%20isolates%2C%20leave%20potentially%20little%20time%20to%20gather%20historical%20knowledge%20informative%20on%20the%20ancient%20history%20of%20tuberculosis%20in%20West-Africa.%22%2C%22date%22%3A%222023-10-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pntd.0011619%22%2C%22ISSN%22%3A%221935-2735%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdx.plos.org%5C%2F10.1371%5C%2Fjournal.pntd.0011619%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-12-31T15%3A29%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22CUDV3QRA%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22G%5Cu00fcnther%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EG%26%23xFC%3Bnther%2C%20G.%2C%20Guglielmetti%2C%20L.%2C%20Leu%2C%20C.%2C%20van%20Leth%2C%20F.%20and%20Lange%2C%20C.%20%282023%29.%20%3Cb%3ERelative%20cost%20of%20multidrug-resistant%20TB%20medicines%20in%20Europe%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E27%3C%5C%2Fi%3E%2C%20341%26%23x2013%3B344%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.23.0026%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.23.0026%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Relative%20cost%20of%20multidrug-resistant%20TB%20medicines%20in%20Europe%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22G%5Cu00fcnther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Leu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22van%20Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Lange%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-05-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.23.0026%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-06-28T12%3A40%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22CPD8NT5H%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Campbell%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECampbell%2C%20J.%20R.%2C%20Chan%2C%20E.%20D.%2C%20Anderson%2C%20L.%20F.%2C%20Bonnet%2C%20M.%2C%20Brode%2C%20S.%20K.%2C%20Cegielski%2C%20J.%20P.%2C%20Guglielmetti%2C%20L.%2C%20Singla%2C%20R.%2C%20Fox%2C%20G.%20J.%2C%20Skrahina%2C%20A.%2C%20Rodrigues%2C%20D.%2C%20Kuksa%2C%20L.%2C%20Viiklepp%2C%20P.%20and%20Menzies%2C%20D.%20%282023%29.%20%3Cb%3EAssociation%20of%20smoking%20and%20alcohol%20use%20with%20rifampin-resistant%20TB%20treatment%20outcomes%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E27%3C%5C%2Fi%3E%2C%20338%26%23x2013%3B340%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0678%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0678%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20smoking%20and%20alcohol%20use%20with%20rifampin-resistant%20TB%20treatment%20outcomes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20R.%22%2C%22lastName%22%3A%22Campbell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20D.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20F.%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20K.%22%2C%22lastName%22%3A%22Brode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Cegielski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Singla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20J.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Kuksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Viiklepp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Menzies%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-04-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.22.0678%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-06-28T12%3A41%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22WNCRMSUT%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guthmann%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-23%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuthmann%2C%20J.-P.%2C%20Fraisse%2C%20P.%2C%20Bonnet%2C%20I.%20and%20Robert%2C%20J.%20%282023%29.%20%3Cb%3EActive%20tuberculosis%20screening%20among%20the%20displaced%20population%20fleeing%20Ukraine%2C%20France%2C%20February%20to%20October%202022%3C%5C%2Fb%3E.%20Eurosurveillance%20%3Ci%3E28%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2807%5C%2F1560-7917.ES.2023.28.12.2300155%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2807%5C%2F1560-7917.ES.2023.28.12.2300155%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Active%20tuberculosis%20screening%20among%20the%20displaced%20population%20fleeing%20Ukraine%2C%20France%2C%20February%20to%20October%202022%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Paul%22%2C%22lastName%22%3A%22Guthmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Fraisse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22Persons%20fleeing%20Ukraine%20since%20February%202022%20have%20potentially%20higher%20risk%20of%20tuberculosis%20%28TB%29%20vs%20all%20European%20Union%20countries.%20Interest%20of%20active%20TB%20screening%20among%20this%20population%20is%20debated%20and%20not%20widely%20adopted.%20In%20this%20screening%20intervention%20by%20a%20network%20of%20TB%20centres%20in%20France%2C%20the%20number%20needed%20to%20screen%20%28NNS%29%20was%20862%20to%20find%20one%20case.%20This%20experience%20shows%20that%20this%20strategy%20may%20be%20relevant%20for%20TB%20control%20in%20situations%20of%20massive%20displacement%2C%20similar%20to%20that%20following%20the%20Russian%20invasion.%22%2C%22date%22%3A%222023-03-23%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.2807%5C%2F1560-7917.ES.2023.28.12.2300155%22%2C%22ISSN%22%3A%221560-7917%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.eurosurveillance.org%5C%2Fcontent%5C%2F10.2807%5C%2F1560-7917.ES.2023.28.12.2300155%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-03-27T15%3A02%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22UJGH7XG2%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Aubry%20and%20Veziris%22%2C%22parsedDate%22%3A%222023-03-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAubry%2C%20A.%20and%20Veziris%2C%20N.%20%282023%29.%20%3Cb%3ELa%20tuberculose%2C%20l%26%23x2019%3Bune%20des%20plus%20anciennes%20maladies%20infectieuses%26%23x202F%3B%3A%20quelles%20avanc%26%23xE9%3Bes%20r%26%23xE9%3Bcentes%20majeures%26%23x202F%3B%3F%3C%5C%2Fb%3E%20Med%20Sci%20%28Paris%29%20%3Ci%3E39%3C%5C%2Fi%3E%2C%20203%26%23x2013%3B204%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1051%5C%2Fmedsci%5C%2F2023054%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1051%5C%2Fmedsci%5C%2F2023054%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22La%20tuberculose%2C%20l%5Cu2019une%20des%20plus%20anciennes%20maladies%20infectieuses%20%3A%20quelles%20avanc%5Cu00e9es%20r%5Cu00e9centes%20majeures%20%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22m%26eacute%3Bdecine%5C%2Fsciences%20%28M%5C%2FS%29%2C%20revue%20internationale%20dans%20le%20domaine%20de%20la%20recherche%20biologique%2C%20m%26eacute%3Bdicale%20et%20en%20sant%26eacute%3B%22%2C%22date%22%3A%222023%5C%2F03%5C%2F01%22%2C%22language%22%3A%22fr%22%2C%22DOI%22%3A%2210.1051%5C%2Fmedsci%5C%2F2023054%22%2C%22ISSN%22%3A%220767-0974%2C%201958-5381%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.medecinesciences.org%5C%2Farticles%5C%2Fmedsci%5C%2Fabs%5C%2F2023%5C%2F03%5C%2Fmsc230068%5C%2Fmsc230068.html%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-06-28T12%3A27%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22GXEAIVT5%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Masini%20et%20al.%22%2C%22parsedDate%22%3A%222023-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMasini%2C%20T.%2C%20Furin%2C%20J.%2C%20Udwadia%2C%20Z.%20and%20Guglielmetti%2C%20L.%20%282023%29.%20%3Cb%3EOptimal%20management%20of%20drug-resistant%20tuberculosis%3A%20Can%20India%20lead%20the%20way%3F%3C%5C%2Fb%3E%20Indian%20Journal%20of%20Medical%20Research%20%3Ci%3E157%3C%5C%2Fi%3E%2C%20220%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4103%5C%2Fijmr.ijmr_300_23%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4103%5C%2Fijmr.ijmr_300_23%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Optimal%20management%20of%20drug-resistant%20tuberculosis%3A%20Can%20India%20lead%20the%20way%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiziana%22%2C%22lastName%22%3A%22Masini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Furin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zarir%22%2C%22lastName%22%3A%22Udwadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22An%20abstract%20is%20unavailable.%22%2C%22date%22%3A%22Feb-Mar%202023%22%2C%22language%22%3A%22en-US%22%2C%22DOI%22%3A%2210.4103%5C%2Fijmr.ijmr_300_23%22%2C%22ISSN%22%3A%220971-5916%20%28Print%29%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.lww.com%5C%2Fijmr%5C%2FFulltext%5C%2F2023%5C%2F02000%5C%2FOptimal_management_of_drug_resistant_tuberculosis_.17.aspx%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-06-28T12%3A40%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22Q5BS6SYV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dom%5Cu00ednguez%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDom%26%23xED%3Bnguez%2C%20Jos%26%23xE9%3B%2C%20Boeree%2C%20M.%20J.%2C%20Cambau%2C%20E.%2C%20Chesov%2C%20D.%2C%20Conradie%2C%20F.%2C%20Cox%2C%20V.%2C%20Dheda%2C%20K.%2C%20Dudnyk%2C%20A.%2C%20Farhat%2C%20M.%20R.%2C%20Gagneux%2C%20S.%2C%20Grobusch%2C%20M.%20P.%2C%20Gr%26%23xF6%3Bschel%2C%20M.%20I.%2C%20Guglielmetti%2C%20L.%2C%20Kontsevaya%2C%20I.%2C%20Lange%2C%20B.%2C%20van%20Leth%2C%20F.%2C%20Lienhardt%2C%20C.%2C%20Mandalakas%2C%20Anna%20M%2C%20Maurer%2C%20F.%20P.%2C%20Merker%2C%20M.%2C%20Miotto%2C%20P.%2C%20Molina-Moya%2C%20B.%2C%20Morel%2C%20F.%2C%20Niemann%2C%20S.%2C%20Veziris%2C%20N.%2C%20Whitelaw%2C%20A.%2C%20Horsburgh%2C%20Charles%20R%2C%20Lange%2C%20C.%2C%20Dom%26%23xED%3Bnguez%2C%20Jose%2C%20Boeree%2C%20M.%20J.%2C%20Cambau%2C%20E.%2C%20Chesov%2C%20D.%2C%20Conradie%2C%20F.%2C%20Cox%2C%20V.%2C%20Dheda%2C%20K.%2C%20Dudnyk%2C%20A.%2C%20Farhat%2C%20M.%20R.%2C%20Gagneux%2C%20S.%2C%20Grobusch%2C%20M.%20P.%2C%20Gr%26%23xF6%3Bschel%2C%20M.%20I.%2C%20Guglielmetti%2C%20L.%2C%20Kontsevaya%2C%20I.%2C%20Lange%2C%20B.%2C%20van%20Leth%2C%20F.%2C%20Lienhardt%2C%20C.%2C%20Mandalakas%2C%20Anna%20Maria%2C%20Maurer%2C%20F.%2C%20Merker%2C%20M.%2C%20Miotto%2C%20P.%2C%20Molina-Moya%2C%20B.%2C%20Morel%2C%20F.%2C%20Niemann%2C%20S.%2C%20Veziris%2C%20N.%2C%20Whitelaw%2C%20A.%2C%20Horsburgh%2C%20Charles%20Robert%20and%20Lange%2C%20C.%20%282023%29.%20%3Cb%3EClinical%20implications%20of%20molecular%20drug%20resistance%20testing%20for%20Mycobacterium%20tuberculosis%3A%20a%202023%20TBnet%5C%2FRESIST-TB%20consensus%20statement%3C%5C%2Fb%3E.%20The%20Lancet%20Infectious%20Diseases%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2822%2900875-1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2822%2900875-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20implications%20of%20molecular%20drug%20resistance%20testing%20for%20Mycobacterium%20tuberculosis%3A%20a%202023%20TBnet%5C%2FRESIST-TB%20consensus%20statement%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Dom%5Cu00ednguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20J%22%2C%22lastName%22%3A%22Boeree%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dumitru%22%2C%22lastName%22%3A%22Chesov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Conradie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivian%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrii%22%2C%22lastName%22%3A%22Dudnyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%20R%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Gagneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20P%22%2C%22lastName%22%3A%22Grobusch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%20I%22%2C%22lastName%22%3A%22Gr%5Cu00f6schel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irina%22%2C%22lastName%22%3A%22Kontsevaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berit%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22van%20Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Lienhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20M%22%2C%22lastName%22%3A%22Mandalakas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%20P%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Merker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Molina-Moya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Whitelaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20R%22%2C%22lastName%22%3A%22Horsburgh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Dom%5Cu00ednguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20J.%22%2C%22lastName%22%3A%22Boeree%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dumitru%22%2C%22lastName%22%3A%22Chesov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Conradie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivian%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrii%22%2C%22lastName%22%3A%22Dudnyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%20R.%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Gagneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20P.%22%2C%22lastName%22%3A%22Grobusch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%20I.%22%2C%22lastName%22%3A%22Gr%5Cu00f6schel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irina%22%2C%22lastName%22%3A%22Kontsevaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berit%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22van%20Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Lienhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Maria%22%2C%22lastName%22%3A%22Mandalakas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Merker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Molina-Moya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Whitelaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20Robert%22%2C%22lastName%22%3A%22Horsburgh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%5D%2C%22abstractNote%22%3A%22Drug-resistant%20tuberculosis%20is%20a%20substantial%20health-care%20concern%20worldwide.%20Despite%20culture-based%20methods%20being%20considered%20the%20gold%20standard%20for%20drug%20susceptibility%20testing%2C%20molecular%20methods%20provide%20rapid%20information%20about%20the%20Mycobacterium%20tuberculosis%20mutations%20associated%20with%20resistance%20to%20anti-tuberculosis%20drugs.%20This%20consensus%20document%20was%20developed%20on%20the%20basis%20of%20a%20comprehensive%20literature%20search%2C%20by%20the%20TBnet%20and%20RESIST-TB%20networks%2C%20about%20reporting%20standards%20for%20the%20clinical%20use%20of%20molecular%20drug%20susceptibility%20testing.%20Review%20and%20the%20search%20for%20evidence%20included%20hand-searching%20journals%20and%20searching%20electronic%20databases.%20The%20panel%20identified%20studies%20that%20linked%20mutations%20in%20genomic%20regions%20of%20M%20tuberculosis%20with%20treatment%20outcome%20data.%20Implementation%20of%20molecular%20testing%20for%20the%20prediction%20of%20drug%20resistance%20in%20M%20tuberculosis%20is%20key.%20Detection%20of%20mutations%20in%20clinical%20isolates%20has%20implications%20for%20the%20clinical%20management%20of%20patients%20with%20multidrug-resistant%20or%20rifampicin-resistant%20tuberculosis%2C%20especially%20in%20situations%20when%20phenotypic%20drug%20susceptibility%20testing%20is%20not%20available.%20A%20multidisciplinary%20team%20including%20clinicians%2C%20microbiologists%2C%20and%20laboratory%20scientists%20reached%20a%20consensus%20on%20key%20questions%20relevant%20to%20molecular%20prediction%20of%20drug%20susceptibility%20or%20resistance%20to%20M%20tuberculosis%2C%20and%20their%20implications%20for%20clinical%20practice.%20This%20consensus%20document%20should%20help%20clinicians%20in%20the%20management%20of%20patients%20with%20tuberculosis%2C%20providing%20guidance%20for%20the%20design%20of%20treatment%20regimens%20and%20optimising%20outcomes.%22%2C%22date%22%3A%222023-02-28%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2FS1473-3099%2822%2900875-1%22%2C%22ISSN%22%3A%221473-3099%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1473309922008751%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-03-10T14%3A55%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22CVEKMV76%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Barbier%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBarbier%2C%20E.%2C%20Fouchet%2C%20T.%2C%20Hartmann%2C%20A.%2C%20Cambau%2C%20E.%2C%20Mougari%2C%20F.%2C%20Dubois%2C%20C.%2C%20Lubetzki%2C%20M.%20and%20Rochelet%2C%20M.%20%282023%29.%20%3Cb%3ERapid%20electrochemical%20detection%20of%20Mycobacterium%20tuberculosis%20in%20sputum%20by%20measuring%20Ag85%20activity%20with%20disposable%20carbon%20sensors%3C%5C%2Fb%3E.%20Talanta%20%3Ci%3E253%3C%5C%2Fi%3E%2C%20123927%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.talanta.2022.123927%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.talanta.2022.123927%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rapid%20electrochemical%20detection%20of%20Mycobacterium%20tuberculosis%20in%20sputum%20by%20measuring%20Ag85%20activity%20with%20disposable%20carbon%20sensors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Barbier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Th%5Cu00e9o%22%2C%22lastName%22%3A%22Fouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Hartmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Lubetzki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Murielle%22%2C%22lastName%22%3A%22Rochelet%22%7D%5D%2C%22abstractNote%22%3A%22An%20electrochemical%20assay%20for%20the%20detection%20of%20the%20enzymatic%20activity%20of%20the%20antigen%2085%20%28Ag85%29%20tuberculosis%20%28TB%29%20biomarker%20was%20developed%20and%20evaluated%20for%20the%20qualitative%20detection%20of%20Mycobacterium%20tuberculosis%20in%20decontaminated%20sputum.%20For%20this%20purpose%2C%20the%20electroactive%20properties%20of%20both%20synthetic%20p-aminophenyl-6-O-octanoyl-3-d-glucopyranoside%20%28p-APOG%29%20substrate%20and%20p-aminophenyl-6-3-d-glucopyranoside%20%28p-APG%29%20product%20released%20after%20the%20removal%20of%20the%20octanoyl%20fatty%20acid%20by%20the%20Ag85%20were%20investigated%20with%20disposable%20carbon%20screen-printed%20electrodes%20by%20cyclic%20voltammetry.%20Since%20specific%20anodic%20responses%20were%20obtained%20for%20the%20p-APOG%20substrate%20and%20the%20p-APG%20product%2C%20the%20intensity%20of%20the%20oxidation%20peak%20of%20the%20p-APG%20%28E%5Cu00a0%3D%5Cu00a0%2B%200.35%5Cu00a0V%20vs.%20Ag%5C%2FAgCl%29%20was%20selected%20as%20the%20analytical%20response%20for%20the%20detection%20of%20the%20Ag85%20acyltransferase%20activity.%20Once%20the%20proof%20of%20concept%20of%20the%20Ag85%20electrochemical%20assay%20was%20validated%20with%20a%20commercially-available%20Ag85B%20protein%2C%20its%20specificity%20was%20further%20assessed%20by%20analyzing%20pure%20cultures%20of%20various%20bacteria%20including%20tuberculous%20and%20non-tuberculous%20mycobacteria%20as%20well%20as%20different%20species%20found%20in%20patients%27%20sputum.%20Finally%2C%20with%20a%20specificity%20of%2078%25%20and%20a%20sensitivity%20of%2089%25%2C%20the%20method%20was%20successfully%20compared%20to%20microscopy%20and%20culture%20routine%20tests%20for%20TB%20testing%20in%2036%20frozen%20fluidized%20and%20decontaminated%20sputum.%20This%20suggests%20that%20owing%20to%20its%20convenience%2C%20rapidity%2C%20low-cost%20and%20portability%2C%20the%20reported%20Ag85%20electrochemical%20assay%20is%20a%20promising%20tool%20to%20screen%20patients%20for%20TB.%22%2C%22date%22%3A%222023-02-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.talanta.2022.123927%22%2C%22ISSN%22%3A%220039-9140%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0039914022007238%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A13%3A06Z%22%7D%7D%2C%7B%22key%22%3A%226W5JQ546%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khan%20and%20Guglielmetti%22%2C%22parsedDate%22%3A%222023-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKhan%2C%20U.%20and%20Guglielmetti%2C%20L.%20%282023%29.%20%3Cb%3ETailored%20TPT%20for%20drug-resistant%20TB%20-%20promoting%20equity%20and%20access%20to%20optimal%20care%3C%5C%2Fb%3E.%20Int%20J%20Tuberc%20Lung%20Dis%20%3Ci%3E27%3C%5C%2Fi%3E%2C%2089b%26%23x2013%3B890%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0538%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0538%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tailored%20TPT%20for%20drug-resistant%20TB%20-%20promoting%20equity%20and%20access%20to%20optimal%20care%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-01-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.22.0538%22%2C%22ISSN%22%3A%221815-7920%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-03-10T14%3A58%3A55Z%22%7D%7D%2C%7B%22key%22%3A%2227ERGIBY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22G%5Cu00fcnther%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EG%26%23xFC%3Bnther%2C%20G.%2C%20Guglielmetti%2C%20L.%2C%20Leu%2C%20C.%2C%20Lange%2C%20C.%2C%20van%20Leth%2C%20F.%2C%20Hasan%20Hafizi%2C%20Khachatryan%2C%20N.%2C%20Aroyan%2C%20H.%2C%20Kabasakalyan%2C%20E.%2C%20Knappik%2C%20M.%2C%20Skrahina%2C%20A.%2C%20Klimuk%2C%20D.%2C%20Nikolenka%2C%20A.%2C%20Muylle%2C%20I.%2C%20Milanov%2C%20V.%2C%20Velkovska%2C%20D.%2C%20Tarinska%2C%20N.%2C%20Bachiyska%2C%20E.%2C%20Jankovic%2C%20M.%2C%20Pieridou%2C%20D.%2C%20Adamide%2C%20T.%2C%20Nicolaou%2C%20N.%2C%20Vasakova%2C%20M.%2C%20Sukholytka%2C%20M.%2C%20Kopeck%26%23xE0%3B%2C%20E.%2C%20Folkvardsen%2C%20D.%20B.%2C%20Svensson%2C%20E.%2C%20Danilovits%2C%20M.%2C%20Kummik%2C%20T.%2C%20Vasankari%2C%20T.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Nahmiash%2C%20A.%2C%20Togonidze%2C%20T.%2C%20Avaliani%2C%20Z.%2C%20Kinkladze%2C%20I.%2C%20Aspindzelashvili%2C%20R.%2C%20Bichashvili%2C%20T.%2C%20Losaberidze%2C%20G.%2C%20Merabishvili%2C%20T.%2C%20Kalsdorf%2C%20B.%2C%20Manika%2C%20K.%2C%20Tsiakitzis%2C%20K.%2C%20Bakos%2C%20A.%2C%20%26%23xC6%3Bgisd%26%23xF3%3Bttir%2C%20T.%20R.%2C%20Michelsen%2C%20G.%20S.%2C%20Karlsd%26%23xF3%3Bttir%2C%20K.%2C%20McLaughlin%2C%20A.-M.%2C%20Fitzgibbon%2C%20M.%2C%20Chemtob%2C%20D.%2C%20Codecasa%2C%20L.%20R.%2C%20Ferrarese%2C%20M.%2C%20Torri%2C%20S.%2C%20Gjocaj%2C%20M.%2C%20Kuksa%2C%20L.%2C%20Davidaviciene%2C%20E.%2C%20Wirtz%2C%20G.%2C%20Perrin%2C%20M.%2C%20Asciak%2C%20A.%20P.%2C%20Chesov%2C%20D.%2C%20de%20Lange%2C%20W.%2C%20Akkerman%2C%20O.%2C%20Poposka%2C%20B.%20I.%2C%20Mack%2C%20U.%2C%20Jensenius%2C%20M.%2C%20Kvalvik%2C%20L.%2C%20Mengshoel%2C%20A.%20T.%2C%20Kruczak%2C%20K.%2C%20Duarte%2C%20R.%2C%20Ribeiro%2C%20N.%2C%20Ibraim%2C%20E.%2C%20Kaluzhenina%2C%20A.%2C%20Barkanova%2C%20O.%2C%20Pesut%2C%20D.%2C%20Solovic%2C%20I.%2C%20Svetina%2C%20P.%2C%20Souza-Galv%26%23xE3%3Bo%2C%20M.-L.%20de%2C%20Millet%2C%20J.-P.%2C%20Casas%2C%20X.%2C%20Vives%2C%20M.%2C%20Bruchfeld%2C%20J.%2C%20Dalemo%2C%20P.%2C%20Jonsson%2C%20J.%2C%20Aeschbacher%2C%20K.%2C%20Keller%2C%20P.%2C%20%26%23xD6%3Bzkara%2C%20S.%2C%20Tiberi%2C%20S.%2C%20Chen%2C%20C.%2C%20Terleeva%2C%20Y.%20and%20Dudnyk%2C%20A.%20%282023%29.%20%3Cb%3EAvailability%20and%20costs%20of%20medicines%20for%20the%20treatment%20of%20tuberculosis%20in%20Europe%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20%3Ci%3E29%3C%5C%2Fi%3E%2C%2077%26%23x2013%3B84%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.07.026%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.07.026%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Availability%20and%20costs%20of%20medicines%20for%20the%20treatment%20of%20tuberculosis%20in%20Europe%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunar%22%2C%22lastName%22%3A%22G%5Cu00fcnther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Leu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22van%20Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Hasan%20Hafizi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naira%22%2C%22lastName%22%3A%22Khachatryan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harut%22%2C%22lastName%22%3A%22Aroyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduard%22%2C%22lastName%22%3A%22Kabasakalyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Knappik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dzmitry%22%2C%22lastName%22%3A%22Klimuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Nikolenka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Inge%22%2C%22lastName%22%3A%22Muylle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladimir%22%2C%22lastName%22%3A%22Milanov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Desislava%22%2C%22lastName%22%3A%22Velkovska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neli%22%2C%22lastName%22%3A%22Tarinska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeta%22%2C%22lastName%22%3A%22Bachiyska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mateja%22%2C%22lastName%22%3A%22Jankovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Despo%22%2C%22lastName%22%3A%22Pieridou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tonia%22%2C%22lastName%22%3A%22Adamide%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicos%22%2C%22lastName%22%3A%22Nicolaou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%22%2C%22lastName%22%3A%22Vasakova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariia%22%2C%22lastName%22%3A%22Sukholytka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%22%2C%22lastName%22%3A%22Kopeck%5Cu00e0%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dorte%20Bek%22%2C%22lastName%22%3A%22Folkvardsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manfred%22%2C%22lastName%22%3A%22Danilovits%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiina%22%2C%22lastName%22%3A%22Kummik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tuula%22%2C%22lastName%22%3A%22Vasankari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Nahmiash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tamar%22%2C%22lastName%22%3A%22Togonidze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zaza%22%2C%22lastName%22%3A%22Avaliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Inga%22%2C%22lastName%22%3A%22Kinkladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rusudan%22%2C%22lastName%22%3A%22Aspindzelashvili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Teona%22%2C%22lastName%22%3A%22Bichashvili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gulnazi%22%2C%22lastName%22%3A%22Losaberidze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tsitsino%22%2C%22lastName%22%3A%22Merabishvili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Kalsdorf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katerina%22%2C%22lastName%22%3A%22Manika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karyofyllis%22%2C%22lastName%22%3A%22Tsiakitzis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnes%22%2C%22lastName%22%3A%22Bakos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tinna%20R%5Cu00e1n%22%2C%22lastName%22%3A%22%5Cu00c6gisd%5Cu00f3ttir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gu%5Cu00f0r%5Cu00fan%20Svanhv%5Cu00edt%22%2C%22lastName%22%3A%22Michelsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krist%5Cu00edn%22%2C%22lastName%22%3A%22Karlsd%5Cu00f3ttir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Marie%22%2C%22lastName%22%3A%22McLaughlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaret%22%2C%22lastName%22%3A%22Fitzgibbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Chemtob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luigi%20R.%22%2C%22lastName%22%3A%22Codecasa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurizio%22%2C%22lastName%22%3A%22Ferrarese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefania%22%2C%22lastName%22%3A%22Torri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Majlinda%22%2C%22lastName%22%3A%22Gjocaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liga%22%2C%22lastName%22%3A%22Kuksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edita%22%2C%22lastName%22%3A%22Davidaviciene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gil%22%2C%22lastName%22%3A%22Wirtz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Perrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Analita%20Pace%22%2C%22lastName%22%3A%22Asciak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dumitri%22%2C%22lastName%22%3A%22Chesov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wiel%22%2C%22lastName%22%3A%22de%20Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Onno%22%2C%22lastName%22%3A%22Akkerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Biljana%20Ilievska%22%2C%22lastName%22%3A%22Poposka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ulrich%22%2C%22lastName%22%3A%22Mack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mogens%22%2C%22lastName%22%3A%22Jensenius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lajla%22%2C%22lastName%22%3A%22Kvalvik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20Torunn%22%2C%22lastName%22%3A%22Mengshoel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katarzyna%22%2C%22lastName%22%3A%22Kruczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elmira%22%2C%22lastName%22%3A%22Ibraim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Kaluzhenina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Barkanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dragica%22%2C%22lastName%22%3A%22Pesut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Solovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petra%22%2C%22lastName%22%3A%22Svetina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria-Luiza%20de%22%2C%22lastName%22%3A%22Souza-Galv%5Cu00e3o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan-Pau%22%2C%22lastName%22%3A%22Millet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavi%22%2C%22lastName%22%3A%22Casas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Montserrat%22%2C%22lastName%22%3A%22Vives%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%22%2C%22lastName%22%3A%22Bruchfeld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paulina%22%2C%22lastName%22%3A%22Dalemo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerker%22%2C%22lastName%22%3A%22Jonsson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katrin%22%2C%22lastName%22%3A%22Aeschbacher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seref%22%2C%22lastName%22%3A%22%5Cu00d6zkara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christabelle%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yana%22%2C%22lastName%22%3A%22Terleeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrii%22%2C%22lastName%22%3A%22Dudnyk%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%5CnTo%20evaluate%20the%20access%20to%20comprehensive%20diagnostics%20and%20novel%20antituberculosis%20medicines%20in%20European%20countries.%5CnMethods%5CnWe%20investigated%20the%20access%20to%20genotypic%20and%20phenotypic%20Mycobacterium%20tuberculosis%20drug%20susceptibility%20testing%20and%20the%20availability%20of%20antituberculosis%20drugs%20and%20calculated%20the%20cost%20of%20drugs%20and%20treatment%20regimens%20at%20major%20tuberculosis%20treatment%20centres%20in%20countries%20of%20the%20WHO%20European%20region%20where%20rates%20of%20drug-resistant%20tuberculosis%20are%20the%20highest%20among%20all%20WHO%20regions.%20Results%20were%20stratified%20by%20middle-income%20and%20high-income%20countries.%5CnResults%5CnOverall%2C%2043%20treatment%20centres%20from%2043%20countries%20participated%20in%20the%20study.%20For%20WHO%20group%20A%20drugs%2C%20the%20frequency%20of%20countries%20with%20the%20availability%20of%20phenotypic%20drug%20susceptibility%20testing%20was%20as%20follows%3A%20%28a%29%2075%25%20%2830%5C%2F40%29%20for%20levofloxacin%2C%20%28b%29%2082%25%20%2833%5C%2F40%29%20for%20moxifloxacin%2C%20%28c%29%2048%25%20%2819%5C%2F40%29%20for%20bedaquiline%2C%20and%20%28d%29%2072%25%20%2829%5C%2F40%29%20for%20linezolid.%20Overall%2C%20of%20the%2043%20countries%2C%2036%20%2884%25%29%20and%2024%20%2856%25%29%20countries%20had%20access%20to%20bedaquiline%20and%20delamanid%2C%20respectively%2C%20whereas%20only%206%20%2814%25%29%20countries%20had%20access%20to%20rifapentine.%20The%20treatment%20of%20patients%20with%20extensively%20drug-resistant%20tuberculosis%20with%20a%20regimen%20including%20a%20carbapenem%20was%20available%20only%20in%2017%20%2840%25%29%20of%20the%2043%20countries.%20The%20median%20cost%20of%20regimens%20for%20drug-susceptible%20tuberculosis%2C%20multidrug-resistant%5C%2Frifampicin-resistant%20tuberculosis%20%28shorter%20regimen%2C%20including%20bedaquiline%20for%206%5Cu00a0months%29%2C%20and%20extensively%20drug-resistant%20tuberculosis%20%28including%20bedaquiline%2C%20delamanid%2C%20and%20a%20carbapenem%29%20were%20%5Cu20ac44%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac15%5Cu2013152%29%2C%20%5Cu20ac764%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac542%5Cu201315152%29%2C%20and%20%5Cu20ac8709%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac7965%5Cu201311759%29%20in%20middle-income%20countries%20%28n%5Cu00a0%3D%5Cu00a012%29%20and%20%5Cu20ac280%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac78%5Cu20131084%29%2C%20%5Cu20ac29765%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac11116%5Cu201340584%29%2C%20and%20%5Cu20ac217591%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac82827%5Cu2013320146%29%20in%20high-income%20countries%20%28n%5Cu00a0%3D%5Cu00a029%29%2C%20respectively.%5CnDiscussion%5CnIn%20countries%20of%20the%20WHO%20European%20region%2C%20there%20is%20a%20widespread%20lack%20of%20drug%20susceptibility%20testing%20capacity%20to%20new%20and%20repurposed%20antituberculosis%20drugs%2C%20lack%20of%20access%20to%20essential%20medications%20in%20several%20countries%2C%20and%20a%20high%20cost%20for%20the%20treatment%20of%20drug-resistant%20tuberculosis.%22%2C%22date%22%3A%222023-01-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2022.07.026%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1198743X22003949%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A07%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22KW8CU9JI%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Senelle%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESenelle%2C%20G.%2C%20Sahal%2C%20M.%20R.%2C%20La%2C%20K.%2C%20Billard-Pomares%2C%20T.%2C%20Marin%2C%20J.%2C%20Mougari%2C%20F.%2C%20Bridier-Nahmias%2C%20A.%2C%20Carbonnelle%2C%20E.%2C%20Cambau%2C%20E.%2C%20Refr%26%23xE9%3Bgier%2C%20G.%2C%20Guyeux%2C%20C.%20and%20Sola%2C%20C.%20%282023%29.%20%3Cb%3ETowards%20the%20reconstruction%20of%20a%20global%20TB%20history%20using%20a%20new%20pipeline%20%26%23x201C%3BTB-Annotator%5C%22%3C%5C%2Fb%3E.%20Tuberculosis%20%3Ci%3E143%3C%5C%2Fi%3E%2C%20102376%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.tube.2023.102376%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.tube.2023.102376%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Towards%20the%20reconstruction%20of%20a%20global%20TB%20history%20using%20a%20new%20pipeline%20%5Cu201cTB-Annotator%5C%22%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetan%22%2C%22lastName%22%3A%22Senelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammed%20Rabiu%22%2C%22lastName%22%3A%22Sahal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22La%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Typhaine%22%2C%22lastName%22%3A%22Billard-Pomares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Marin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Bridier-Nahmias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Carbonnelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guislaine%22%2C%22lastName%22%3A%22Refr%5Cu00e9gier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Guyeux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Sola%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.tube.2023.102376%22%2C%22ISSN%22%3A%2214729792%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1472979223000744%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-12-31T15%3A27%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22KN8HXK6R%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Motta%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMotta%2C%20I.%2C%20Boeree%2C%20M.%2C%20Chesov%2C%20D.%2C%20Dheda%2C%20K.%2C%20G%26%23xFC%3Bnther%2C%20G.%2C%20Horsburgh%2C%20C.%20R.%2C%20Kherabi%2C%20Y.%2C%20Lange%2C%20C.%2C%20Lienhardt%2C%20C.%2C%20McIlleron%2C%20H.%20M.%2C%20Paton%2C%20N.%20I.%2C%20Stagg%2C%20H.%20R.%2C%20Thwaites%2C%20G.%2C%20Udwadia%2C%20Z.%2C%20Van%20Crevel%2C%20R.%2C%20Vel%26%23xE1%3Bsquez%2C%20G.%20E.%2C%20Wilkinson%2C%20R.%20J.%2C%20Guglielmetti%2C%20L.%2C%20Motta%2C%20I.%2C%20Kherabi%2C%20Y.%2C%20Van%20Crevel%2C%20R.%20and%20Guglielmetti%2C%20L.%20%282023%29.%20%3Cb%3ERecent%20advances%20in%20the%20treatment%20of%20tuberculosis%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20S1198743X23003397%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2023.07.013%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2023.07.013%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Recent%20advances%20in%20the%20treatment%20of%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilaria%22%2C%22lastName%22%3A%22Motta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Boeree%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dumitru%22%2C%22lastName%22%3A%22Chesov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunar%22%2C%22lastName%22%3A%22G%5Cu00fcnther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20Robert%22%2C%22lastName%22%3A%22Horsburgh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Lienhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%20M.%22%2C%22lastName%22%3A%22McIlleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%20I.%22%2C%22lastName%22%3A%22Paton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%20R.%22%2C%22lastName%22%3A%22Stagg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Thwaites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zarir%22%2C%22lastName%22%3A%22Udwadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reinout%22%2C%22lastName%22%3A%22Van%20Crevel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%20E.%22%2C%22lastName%22%3A%22Vel%5Cu00e1squez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilaria%22%2C%22lastName%22%3A%22Motta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reinout%22%2C%22lastName%22%3A%22Van%20Crevel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%227%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2023.07.013%22%2C%22ISSN%22%3A%221198743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1198743X23003397%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-11-13T15%3A55%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22A2TD2VUD%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Holmgaard%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHolmgaard%2C%20F.%20B.%2C%20Guglielmetti%2C%20L.%2C%20Lillebaek%2C%20T.%2C%20Andersen%2C%20%26%23xC5%3B.%20B.%2C%20Wejse%2C%20C.%20and%20Dahl%2C%20V.%20N.%20%282022%29.%20%3Cb%3EEfficacy%20and%20tolerability%20of%20concomitant%20use%20of%20bedaquiline%20and%20delamanid%20for%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%3A%20a%20systematic%20review%20and%20meta-analysis%3C%5C%2Fb%3E.%20Clin%20Infect%20Dis%20ciac876%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac876%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac876%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20and%20tolerability%20of%20concomitant%20use%20of%20bedaquiline%20and%20delamanid%20for%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%3A%20a%20systematic%20review%20and%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Freja%20Breth%22%2C%22lastName%22%3A%22Holmgaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Troels%22%2C%22lastName%22%3A%22Lillebaek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c5se%20Bengaard%22%2C%22lastName%22%3A%22Andersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Wejse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%20Naestholt%22%2C%22lastName%22%3A%22Dahl%22%7D%5D%2C%22abstractNote%22%3A%22The%20introduction%20of%20two%20novel%20drugs%2C%20bedaquiline%20and%20delamanid%2C%20has%20given%20hope%20for%20better%20and%20shorter%20treatments%20of%20drug-resistant%20tuberculosis.%20A%20systematic%20review%20was%20conducted%20to%20evaluate%20the%20efficacy%20and%20safety%20of%20concomitant%20bedaquiline%20and%20delamanid%20administration.%20Pooled%20estimates%20of%20WHO-defined%20favorable%20treatment%20outcome%20and%20significant%20QTc-interval%20prolongation%20%28QTc%20%5Cu2265500%5Cu2005ms%20or%20%5Cu226560%5Cu2005ms%20increase%20from%20baseline%29%20were%20calculated%20using%20a%20random%20effects%20model.%20Thirteen%20studies%20including%20a%20total%20of%201031%20individuals%20with%20multidrug-resistant%5C%2Frifampicin-resistant%20tuberculosis%20who%20received%20bedaquiline%20and%20delamanid%20were%20included.%20The%20pooled%20estimate%20of%20favorable%20treatment%20outcome%20was%2073.1%25%20%2895%25CI%3A%2064.3-81.8%29.%20Sputum%20culture%20conversion%20at%20six%20months%20ranged%20from%2061-95%25.%20Overall%2C%20the%20pooled%20proportion%20of%20QTc-prolongation%20was%207.8%25%20%2895%25CI%3A%204.1-11.6%29%20and%20few%20cardiac%20events%20were%20reported%20%280.8%25%2C%20n%5Cu2009%3D%5Cu20096%5C%2F798%29.%20Rates%20of%20sputum%20culture%20conversion%20and%20favorable%20treatment%20outcome%20were%20high%20in%20patients%20treated%20concomitantly%20with%20bedaquiline%20and%20delamanid%2C%20and%20the%20treatment%20seemed%20tolerable%20with%20low%20rates%20of%20clinically%20significant%20cardiac%20toxicity.%22%2C%22date%22%3A%222022-11-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac876%22%2C%22ISSN%22%3A%221537-6591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-03-10T14%3A59%3A47Z%22%7D%7D%2C%7B%22key%22%3A%228NJBYM8Z%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wetzstein%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWetzstein%2C%20N.%2C%20Drummer%2C%20A.-P.%2C%20Bockey%2C%20A.%2C%20Herrmann%2C%20E.%2C%20K%26%23xFC%3Bpper-Tetzel%2C%20C.%20P.%2C%20Graf%2C%20C.%2C%20Koch%2C%20B.%2C%20Goetsch%2C%20U.%2C%20Vehreschild%2C%20M.%20J.%20G.%20T.%2C%20Guglielmetti%2C%20L.%2C%20Lange%2C%20B.%2C%20Wichelhaus%2C%20T.%20A.%20and%20Stephan%2C%20C.%20%282022%29.%20%3Cb%3EOccurrence%20of%20extrapulmonary%20tuberculosis%20is%20associated%20with%20geographical%20origin%3A%20spatial%20characteristics%20of%20the%20Frankfurt%20TB%20cohort%202013%26%23x2013%3B2018%3C%5C%2Fb%3E.%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Occurrence%20of%20extrapulmonary%20tuberculosis%20is%20associated%20with%20geographical%20origin%3A%20spatial%20characteristics%20of%20the%20Frankfurt%20TB%20cohort%202013%5Cu20132018%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nils%22%2C%22lastName%22%3A%22Wetzstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena-Pauline%22%2C%22lastName%22%3A%22Drummer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annabelle%22%2C%22lastName%22%3A%22Bockey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Herrmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claus%20Philippe%22%2C%22lastName%22%3A%22K%5Cu00fcpper-Tetzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiana%22%2C%22lastName%22%3A%22Graf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Koch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Udo%22%2C%22lastName%22%3A%22Goetsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20J.%20G.%20T.%22%2C%22lastName%22%3A%22Vehreschild%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berit%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20A.%22%2C%22lastName%22%3A%22Wichelhaus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Stephan%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20is%20caused%20by%20M.%20tuberculosis%20complex%20%28MTB%29%20and%20pulmonary%20tuberculosis%20%28PTB%29%20is%20its%20classical%20manifestation.%20However%2C%20in%20some%20regions%20of%20the%20world%2C%20extrapulmonary%20TB%20%28EPTB%29%20seems%20to%20be%20more%20frequent.%22%2C%22date%22%3A%222022-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs15010-022-01921-9%22%2C%22ISSN%22%3A%221439-0973%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A07%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22JXJYY2QR%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kherabi%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKherabi%2C%20Y.%2C%20Tunesi%2C%20S.%2C%20Kay%2C%20A.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3EPreventive%20Therapy%20for%20Contacts%20of%20Drug-Resistant%20Tuberculosis%3C%5C%2Fb%3E.%20Pathogens%20%3Ci%3E11%3C%5C%2Fi%3E%2C%201189%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fpathogens11101189%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fpathogens11101189%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preventive%20Therapy%20for%20Contacts%20of%20Drug-Resistant%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Kay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22Preventing%20the%20progression%20of%20a%20drug-resistant%20tuberculosis%20%28DR-TB%29%20infection%20to%20disease%20is%20an%20important%20pillar%20of%20the%20DR-TB%20elimination%20strategy.%20International%20guidelines%20have%20recently%20proposed%20fluoroquinolones%20for%20tuberculosis%20preventive%20therapy%20%28TPT%29%20in%20DR-TB%20contacts%2C%20although%20the%20available%20evidence%20is%20low%20quality.%20The%20pooled%20data%20from%20small%20observational%20studies%20suggest%20that%20a%20fluoroquinolone-based%20TPT%20is%20safe%2C%20effective%20and%20cost-effective%20as%20a%20preventive%20treatment%20in%20DR-TB%20contacts.%20Three%20clinical%20trials%20are%20currently%20ongoing%20to%20generate%20higher%20quality%20evidence%20on%20the%20efficacy%20of%20levofloxacin%20and%20delamanid%20as%20a%20DR-TB%20preventive%20therapy.%20Additional%20evidence%20is%20also%20needed%2C%20regarding%20TPT%20treatment%20in%20fluoroquinolone-resistant-TB%20contacts%2C%20patient%20and%20health%20care%20worker%20perceptions%20on%20DR-TB%20preventive%20therapy%20for%20contacts%2C%20and%20the%20service%20delivery%20models%20to%20increase%20DR-TPT%20access.%20This%20state-of-the-art%20review%20presents%20the%20current%20literature%20on%20TPT%20for%20contacts%20of%20DR-TB%20cases%2C%20focusing%20on%20the%20available%20evidence%20and%20international%20guidelines.%22%2C%22date%22%3A%222022%5C%2F10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fpathogens11101189%22%2C%22ISSN%22%3A%222076-0817%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2076-0817%5C%2F11%5C%2F10%5C%2F1189%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A07%3A55Z%22%7D%7D%2C%7B%22key%22%3A%224ND3DBVZ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khan%20and%20Guglielmetti%22%2C%22parsedDate%22%3A%222022-09-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKhan%2C%20U.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3EEvidence%20and%20ethical%20considerations%20for%20the%20treatment%20of%20contacts%20exposed%20to%20drug-resistant%20TB%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E26%3C%5C%2Fi%3E%2C%20900%26%23x2013%3B901%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0328%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0328%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evidence%20and%20ethical%20considerations%20for%20the%20treatment%20of%20contacts%20exposed%20to%20drug-resistant%20TB%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-09-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.22.0328%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-04-26T13%3A17%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22YKWPDBTM%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kherabi%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKherabi%2C%20Y.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Rioux%2C%20C.%2C%20Yazdanpanah%2C%20Y.%2C%20M%26%23xE9%3Bcha%26%23xEF%3B%2C%20F.%2C%20Pourcher%2C%20V.%2C%20Robert%2C%20J.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3ERevised%20Definitions%20of%20Tuberculosis%20Resistance%20and%20Treatment%20Outcomes%2C%20France%2C%202006%26%23x2013%3B2019%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%201796%26%23x2013%3B1804%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2809.220458%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2809.220458%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Revised%20Definitions%20of%20Tuberculosis%20Resistance%20and%20Treatment%20Outcomes%2C%20France%2C%202006%5Cu20132019%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22M%5Cu00e9cha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22Definitions%20of%20resistance%20in%20multidrug-resistant%20tuberculosis%20%28MDR%20TB%29%20and%20extensively%20drug-resistant%20tuberculosis%20%28XDR%20TB%29%20have%20been%20updated.%20Pre%5Cu2013XDR%20TB%2C%20defined%20as%20MDR%20TB%20with%20additional%20resistance%20to%20fluoroquinolones%2C%20and%20XDR%20TB%2C%20with%20additional%20resistance%20to%20bedaquiline%20or%20linezolid%2C%20are%20frequently%20associated%20with%20treatment%20failure%20and%20toxicity.%20We%20retrospectively%20determined%20the%20effects%20of%20pre-XDR%5C%2FXDR%20TB%20resistance%20on%20outcomes%20and%20safety%20of%20MDR%20TB%20treatment%20in%20France.%20The%20study%20included%20298%20patients%20treated%20for%20MDR%20TB%20at%203%20reference%20centers%20during%202006%5Cu20132019.%20Of%20those%2C%20205%20%2868.8%25%29%20cases%20were%20fluoroquinolone-susceptible%20MDR%20TB%20and%2093%20%2831.2%25%29%20were%20pre-XDR%5C%2FXDR%20TB.%20Compared%20with%20fluoroquinolone-susceptible%20MDR%20TB%2C%20pre-XDR%5C%2FXDR%20TB%20was%20associated%20with%20more%20cavitary%20lung%20lesions%20and%20bilateral%20disease%20and%20required%20longer%20treatment.%20Overall%2C%20202%20patients%20%2867.8%25%29%20had%20favorable%20treatment%20outcomes%2C%20with%20no%20significant%20difference%20between%20pre-XDR%5C%2FXDR%20TB%20%2867.7%25%29%20and%20fluoroquinolone-susceptible%20MDR%20TB%20%2867.8%25%3B%20p%20%3D%200.99%29.%20Pre-XDR%5C%2FXDR%20TB%20was%20not%20associated%20with%20higher%20risk%20for%20serious%20adverse%20events.%22%2C%22date%22%3A%222022-9%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2809.220458%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9423894%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A14%3A59Z%22%7D%7D%2C%7B%22key%22%3A%2232L5JEUW%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22De%20Castro%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDe%20Castro%2C%20N.%2C%20Mecha%26%23xEF%3B%2C%20F.%2C%20Bachelet%2C%20D.%2C%20Canestri%2C%20A.%2C%20Joly%2C%20V.%2C%20Vandenhende%2C%20M.%2C%20Boutoille%2C%20D.%2C%20Kerjouan%2C%20M.%2C%20Veziris%2C%20N.%2C%20Molina%2C%20J.%20M.%2C%20Grall%2C%20N.%2C%20Tattevin%2C%20P.%2C%20Laou%26%23xE9%3Bnan%2C%20C.%2C%20Yazdanpanah%2C%20Y.%20and%20for%20the%20FAST%20TB%20Study%20Group%20%282022%29.%20%3Cb%3ETreatment%20With%20a%20Three-Drug%20Regimen%20for%20Pulmonary%20Tuberculosis%20Based%20on%20Rapid%20Molecular%20Detection%20of%20Isoniazid%20Resistance%3A%20A%20Noninferiority%20Randomized%20Trial%20%28FAST-TB%29%3C%5C%2Fb%3E.%20Open%20Forum%20Infectious%20Diseases%20%3Ci%3E9%3C%5C%2Fi%3E%2C%20ofac353%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Treatment%20With%20a%20Three-Drug%20Regimen%20for%20Pulmonary%20Tuberculosis%20Based%20on%20Rapid%20Molecular%20Detection%20of%20Isoniazid%20Resistance%3A%20A%20Noninferiority%20Randomized%20Trial%20%28FAST-TB%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22De%20Castro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Mecha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Bachelet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Canestri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Joly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Vandenhende%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Boutoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kerjouan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Grall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Tattevin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Laou%5Cu00e9nan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20FAST%20TB%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22The%20rationale%20behind%20the%20use%20of%20ethambutol%20in%20the%20standard%20tuberculosis%20treatment%20is%20to%20prevent%20the%20emergence%20of%20resistance%20to%20rifampicin%20in%20case%20of%20primary%20resistance%20to%20isoniazid.%20We%20evaluated%20whether%20early%20detection%20of%20isoniazid%20resistance%20using%20molecular%20testing%20allows%20the%20use%20an%20ethambutol-free%20regimen.FAST-TB%2C%20a%20phase%204%2C%20French%2C%20multicenter%2C%20open-label%2C%20non-inferiority%20trial%2C%20compared%202%20strategies%3A%20%281%29%20polymerase%20chain%20reaction%20%28PCR%29-based%20detection%20of%20isoniazid%20and%20rifampicin%20resistance%20at%20baseline%20using%20Genotype%20MTBDRplus%20version%202.0%20followed%20by%20ethambutol%20discontinuation%20if%20no%20resistance%20was%20detected%20%28PCR%20arm%29%20and%20%282%29%20a%20standard%204-drug%20combination%2C%20pending%20phenotypic%20drug-susceptibility%20results%20%28C%20arm%29.%20Adult%20patients%20with%20smear-positive%20pulmonary%20tuberculosis%20were%20enrolled.%20The%20primary%20endpoint%20was%20the%20proportion%20of%20patients%20with%20treatment%20success%20defined%20as%20bacteriological%20or%20clinical%20cure%20at%20the%20end%20of%20treatment.%20A%20non-inferiority%20margin%20of%2010%25%20was%20used.Two%20hundred%20three%20patients%20were%20randomized%2C%20104%20in%20the%20PCR%20arm%20and%2099%20in%20the%20C%20arm%3A%2026.6%25%20were%20female%2C%20median%20age%20was%2037%20%28interquartile%20range%2C%2028%5Cu201351%29%20years%2C%2072.4%25%20were%20born%20in%20Africa%2C%20and%205.4%25%20were%20infected%20with%20human%20immunodeficiency%20virus.%20Chest%20x-ray%20showed%20cavities%20in%2064.5%25%20of%20the%20cases.%20Overall%2C%20169%20patients%20met%20criteria%20of%20treatment%20success%3A%2087%20of%20104%20%2883.7%25%29%20in%20the%20PCR%20arm%20and%2082%20of%2099%20%2882.8%25%29%20in%20the%20C%20arm%20with%20a%20difference%20of%20%2B0.8%25%20%2890%25%20confidence%20interval%2C%20%5Cu22127.9%20to%209.6%29%2C%20meeting%20the%20noninferiority%20criteria%20in%20the%20intention-to-treat%20population%20%28P%5Cu2009%3D%5Cu2009.02%29.In%20a%20setting%20with%20low%20prevalence%20of%20primary%20isoniazid%20resistance%2C%20a%203-drug%20combination%20with%20isoniazid%2C%20rifampicin%2C%20and%20pyrazinamide%2C%20based%20on%20rapid%20detection%20of%20isoniazid%20resistance%20using%20molecular%20testing%2C%20was%20noninferior%20to%20starting%20the%20recommended%204-drug%20regimen.%22%2C%22date%22%3A%222022-08-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofac353%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A20%3A00Z%22%7D%7D%2C%7B%22key%22%3A%224KRX87K9%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kraef%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKraef%2C%20C.%2C%20Lindquist%2C%20E.%2C%20Svensson%2C%20E.%20and%20Cambau%2C%20E.%20%282022%29.%20%3Cb%3EDiagnostic%20toolkit%20for%20tuberculosis%3A%20should%20we%20include%20urine%20lipoarabinomannan%20%28LAM%29%20detection%20in%20the%20WHO%20European%20Region%3F%3C%5C%2Fb%3E%20Clinical%20Microbiology%20and%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.06.022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.06.022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20toolkit%20for%20tuberculosis%3A%20should%20we%20include%20urine%20lipoarabinomannan%20%28LAM%29%20detection%20in%20the%20WHO%20European%20Region%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Kraef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%22%2C%22lastName%22%3A%22Lindquist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-07-05%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2022.06.022%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1198743X22003366%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A28%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22PF5DMFLC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bachir%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBachir%2C%20M.%2C%20Guglielmetti%2C%20L.%2C%20Tunesi%2C%20S.%2C%20Billard-Pomares%2C%20T.%2C%20Chiesi%2C%20S.%2C%20Jaffr%26%23xE9%3B%2C%20J.%2C%20Langris%2C%20H.%2C%20Pourcher%2C%20V.%2C%20Schramm%2C%20F.%2C%20Lema%26%23xEE%3Btre%2C%20N.%20and%20Robert%2C%20J.%20%282022%29.%20%3Cb%3EMolecular%20detection%20of%20isoniazid%20monoresistance%20improves%20tuberculosis%20treatment%3A%20A%20retrospective%20cohort%20in%20France%3C%5C%2Fb%3E.%20Journal%20of%20Infection%20%3Ci%3E85%3C%5C%2Fi%3E%2C%2024%26%23x2013%3B30%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.05.017%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.05.017%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20detection%20of%20isoniazid%20monoresistance%20improves%20tuberculosis%20treatment%3A%20A%20retrospective%20cohort%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marwa%22%2C%22lastName%22%3A%22Bachir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Typhaine%22%2C%22lastName%22%3A%22Billard-Pomares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheila%22%2C%22lastName%22%3A%22Chiesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Jaffr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Langris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Schramm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Lema%5Cu00eetre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%5CnIsoniazid-monoresistant%20tuberculosis%20%28HR-TB%29%20requires%20early%20diagnosis%20and%20adapted%20treatment%20to%20achieve%20optimal%20outcomes.%20The%20primary%20aim%20of%20the%20study%20was%20to%20assess%20the%20impact%20of%20the%20implementation%20of%20rapid%20diagnostic%20tests%20on%20HR-TB%20treatment%20in%20France.%5CnMethods%5CnWe%20designed%20a%20retrospective%20multicentre%20study%20including%20consecutive%20HR-TB%20patients%20diagnosed%20in%202016%20and%202017.%20Implementation%20of%20a%20molecular%20assay%20detecting%20isoniazid%20resistance%20directly%20on%20a%20clinical%20sample%20was%20recorded.%20The%20association%20between%20early%20implementation%20of%20such%20assays%20and%20adequate%20treatment%20was%20assessed%20by%20a%20multivariable%20Cox%20proportional%20hazards%20model.%5CnResults%5CnOverall%2C%2099%20HR-TB%20patients%20were%20included%20from%2020%20University%20Hospitals.%20Among%20all%20smear-positive%20HR-TB%20patients%2C%20only%2026%25%20beneficiated%20from%20early%20molecular%20HR%20detection.%20This%20detection%20was%20independently%20associated%20with%20shorter%20time%20to%20adequate%20treatment%20%28HR%5Cu00a0%3D%5Cu00a02.0%20%5B1.1%5Cu20133.8%5D%2C%20p%5Cu00a0%3D%5Cu00a00.03%29.%5CnConclusion%5CnIn%20our%20study%2C%20molecular%20detection%20of%20HR%20on%20an%20initial%20sample%20was%20independently%20associated%20with%20earlier%20treatment%20adaptation.%22%2C%22date%22%3A%222022-07-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jinf.2022.05.017%22%2C%22ISSN%22%3A%220163-4453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0163445322003061%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-06T13%3A19%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22VG5PNGPC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Morel%2C%20F.%2C%20Brossier%2C%20F.%2C%20Sougakoff%2C%20W.%2C%20Jaffre%2C%20J.%2C%20Cheng%2C%20S.%2C%20Veziris%2C%20N.%2C%20Aubry%2C%20A.%20and%20on%20behalf%20of%20the%20NRC-MyRMA%20%282022%29.%20%3Cb%3EHow%20a%20PCR%20Sequencing%20Strategy%20Can%20Bring%20New%20Data%20to%20Improve%20the%20Diagnosis%20of%20Ethionamide%20Resistance%3C%5C%2Fb%3E.%20Microorganisms%20%3Ci%3E10%3C%5C%2Fi%3E%2C%201436%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10071436%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10071436%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22How%20a%20PCR%20Sequencing%20Strategy%20Can%20Bring%20New%20Data%20to%20Improve%20the%20Diagnosis%20of%20Ethionamide%20Resistance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9remy%22%2C%22lastName%22%3A%22Jaffre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sokleaph%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20NRC-MyRMA%22%7D%5D%2C%22abstractNote%22%3A%22Ethionamide%20%28ETH%29%20is%20a%20second-line%20antituberculosis%20drug.%20ETH%20resistance%20%28ETH-R%29%20is%20mainly%20related%20to%20the%20mutations%20of%20the%20monooxygenase-activating%20ETH%20%28EthA%29%2C%20the%20ETH%20target%20%28InhA%29%2C%20and%20the%20inhA%20promoter.%20Nonetheless%2C%20diagnosing%20ETH-R%20is%20still%20challenging.%20We%20assessed%20the%20strategy%20used%20for%20detecting%20ETH-R%20at%20the%20French%20National%20Reference%20Center%20for%20Mycobacteria%20in%20497%20MDR-TB%20isolates%20received%20from%202008%20to%202016.%20The%20genotypic%20ETH%5Cu2019s%20resistance%20detection%20was%20performed%20by%20sequencing%20ethA%2C%20ethR%2C%20the%20ethA-ethR%20intergenic%20region%2C%20and%20the%20inhA%20promoter%20in%20the%20497%20multidrug-resistant%20isolates%2C%20whereas%20the%20phenotypic%20ETH%20susceptibility%20testing%20%28PST%29%20was%20performed%20using%20the%20reference%20proportion%20method.%20Mutations%20were%20found%20in%20up%20to%2076%25%20of%20the%20387%20resistant%20isolates%20and%20in%20up%20to%2028%25%20of%20the%20110%20susceptible%20isolates.%20Our%20results%20do%20not%20support%20the%20role%20of%20ethR%20mutations%20in%20ETH%20resistance.%20Altogether%2C%20the%20positive%20predictive%20value%20of%20our%20genotypic%20strategy%20to%20diagnose%20ETH-R%20was%20improved%20when%20only%20considering%20the%20variants%20included%20in%20the%20WHO%20catalogue%20and%20in%20other%20databases%2C%20such%20as%20TB-Profiler.%20Therefore%2C%20our%20work%20will%20help%20to%20update%20the%20list%20of%20mutations%20that%20could%20be%20graded%20as%20being%20associated%20with%20resistance%20to%20improve%20ETH-R%20diagnosis.%22%2C%22date%22%3A%222022%5C%2F7%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fmicroorganisms10071436%22%2C%22ISSN%22%3A%222076-2607%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2076-2607%5C%2F10%5C%2F7%5C%2F1436%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A18%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22S6JQ4XIX%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Eimer%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EEimer%2C%20J.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Le%20D%26%23xFB%3B%2C%20D.%2C%20Caumes%2C%20E.%2C%20El-Helali%2C%20N.%2C%20Marigot-Outtandy%2C%20D.%2C%20Mechai%2C%20F.%2C%20Peytavin%2C%20G.%2C%20Pourcher%2C%20V.%2C%20Rioux%2C%20C.%2C%20Yazdanpanah%2C%20Y.%2C%20Robert%2C%20J.%2C%20Guglielmetti%2C%20L.%20and%20for%20the%20LZDM%20group%20%282022%29.%20%3Cb%3EIncreased%20linezolid%20plasma%20concentrations%20are%20associated%20with%20the%20development%20of%20severe%20toxicity%20in%20MDR-TB%20treatment.%3C%5C%2Fb%3E%20Clinical%20Infectious%20Diseases%20ciac485%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increased%20linezolid%20plasma%20concentrations%20are%20associated%20with%20the%20development%20of%20severe%20toxicity%20in%20MDR-TB%20treatment.%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Eimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Le%20D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Najoua%22%2C%22lastName%22%3A%22El-Helali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Mechai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Peytavin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20LZDM%20group%22%7D%5D%2C%22abstractNote%22%3A%22Treatment%20of%20multidrug-resistant%20tuberculosis%20%28MDR-TB%29%20with%20linezolid%20is%20characterized%20by%20high%20rates%20of%20adverse%20events.%20Evidence%20on%20therapeutic%20drug%20monitoring%20to%20predict%20drug%20toxicity%20is%20scarce.%20This%20study%20aimed%20to%20evaluate%20the%20association%20of%20linezolid%20trough%20concentrations%20with%20severe%20toxicity.We%20retrospectively%20assessed%20consecutive%20patients%20started%20on%20linezolid%20for%20MDR-TB%20between%202011%20and%202017.%20The%20primary%20outcome%20was%20severe%20mitochondrial%20toxicity%20%28SMT%29%20due%20to%20linezolid%2C%20defined%20as%20neurotoxicity%20or%20myelotoxicity%20leading%20to%20drug%20discontinuation.%20The%20impact%20of%20plasma%20linezolid%20trough%20concentrations%20%26gt%3B2%5Cu2005mg%5C%2FL%20was%20assessed%20in%20multivariate%20Cox%20proportional%20hazards%20models%20including%20time-varying%20covariates.SMT%20occurred%20in%2057%20of%20146%20included%20patients%20%2839%25%29%20at%20an%20incidence%20rate%20of%200.38%20per%20person-year%20%2895%25CI%200.30-0.49%29.%20A%20maximum%20linezolid%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL%20was%20detected%20in%2052%20patients%20%2835.6%25%29%2C%20while%20the%20mean%20trough%20concentration%20was%20%26gt%3B2%5Cu2005mg%5C%2FL%20in%2022%20%2815%25%29.%20The%20adjusted%20hazard%20ratio%20for%20SMT%20was%202.35%20%2895%25CI%201.26%5Cu20134.38%2C%20p%5Cu2009%3D%5Cu20090.01%29%20in%20patients%20with%20a%20mean%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL%20and%202.63%20%2895%25CI%201.55%5Cu20134.47%2C%20p%5Cu2009%26lt%3B%5Cu20090.01%29%20for%20SMT%20after%20the%20first%20detection%20of%20a%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL.%20In%20an%20exploratory%20analysis%2C%20higher%20maximum%20trough%20concentrations%20were%20dose-dependently%20associated%20with%20toxicity%2C%20while%20lowering%20of%20elevated%20trough%20concentrations%20did%20not%20restore%20baseline%20risk.Linezolid%20trough%20concentrations%20%26gt%3B2%5Cu2005mg%5C%2FL%20are%20strongly%20associated%20with%20the%20development%20of%20severe%20treatment-emergent%20toxicity%20in%20patients%20treated%20for%20MDR-TB.%20Pending%20further%20prospective%20evidence%2C%20an%20individual%20risk-benefit%20assessment%20on%20the%20continuation%20of%20linezolid%20treatment%20is%20warranted%20in%20any%20patient%20with%20trough%20concentrations%20above%202%5Cu2005mg%5C%2FL.%22%2C%22date%22%3A%222022-06-19%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac485%22%2C%22ISSN%22%3A%221058-4838%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-08T13%3A02%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22HUBVTWEL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonnet%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBonnet%2C%20I.%2C%20Haddad%2C%20E.%2C%20Guglielmetti%2C%20L.%2C%20B%26%23xE9%3Bmer%2C%20P.%2C%20Bernard%2C%20L.%2C%20Bourgoin%2C%20A.%2C%20Brault%2C%20R.%2C%20Catho%2C%20G.%2C%20Caumes%2C%20E.%2C%20Escaut%2C%20L.%2C%20Fourniols%2C%20E.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Gaudart%2C%20A.%2C%20Guillot%2C%20H.%2C%20Lafon-Desmurs%2C%20B.%2C%20Lanoix%2C%20J.-P.%2C%20Lanotte%2C%20P.%2C%20Lemaignen%2C%20A.%2C%20Lemaire%2C%20B.%2C%20Lemaitre%2C%20N.%2C%20Michau%2C%20C.%2C%20Morand%2C%20P.%2C%20Mougari%2C%20F.%2C%20Marigot-Outtandy%2C%20D.%2C%20Patrat-Delon%2C%20S.%2C%20Perpoint%2C%20T.%2C%20Piau%2C%20C.%2C%20Pourcher%2C%20V.%2C%20Zarrouk%2C%20V.%2C%20Zeller%2C%20V.%2C%20Veziris%2C%20N.%2C%20Jaur%26%23xE9%3Bguiberry%2C%20S.%20and%20Aubry%2C%20A.%20%282022%29.%20%3Cb%3EClinical%20Features%20and%20Outcome%20of%20Multidrug-Resistant%20Osteoarticular%20Tuberculosis%3A%20A%2012-Year%20Case%20Series%20from%20France%3C%5C%2Fb%3E.%20Microorganisms%20%3Ci%3E10%3C%5C%2Fi%3E%2C%201215%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10061215%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10061215%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20Features%20and%20Outcome%20of%20Multidrug-Resistant%20Osteoarticular%20Tuberculosis%3A%20A%2012-Year%20Case%20Series%20from%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elie%22%2C%22lastName%22%3A%22Haddad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22B%5Cu00e9mer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Bourgoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Brault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaud%22%2C%22lastName%22%3A%22Catho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9lia%22%2C%22lastName%22%3A%22Escaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Fourniols%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Gaudart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Guillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barth%5Cu00e9l%5Cu00e9my%22%2C%22lastName%22%3A%22Lafon-Desmurs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Lanoix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Lanotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Lemaignen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Lemaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Lemaitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Michau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Morand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Patrat-Delon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Perpoint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Piau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Zarrouk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Zeller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Jaur%5Cu00e9guiberry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22The%20optimal%20treatment%20for%20osteoarticular%20infection%20due%20to%20multidrug-resistant%20tuberculosis%20strains%20%28MDR-OATB%29%20remains%20unclear.%20This%20study%20aims%20to%20evaluate%20the%20diagnosis%2C%20management%20and%20outcome%20of%20MDR-OATB%20in%20France.%20We%20present%20a%20case%20series%20of%20MDR-OATB%20patients%20reviewed%20at%20the%20French%20National%20Reference%20Center%20for%20Mycobacteria%20between%202007%20and%202018.%20Medical%20history%20and%20clinical%2C%20microbiological%2C%20treatment%20and%20outcome%20data%20were%20collected.%20Twenty-three%20MDR-OATB%20cases%20were%20reported%2C%20representing%203%25%20of%20all%20concurrent%20MDR-TB%20cases%20in%20France.%20Overall%2C%2017%20were%20male%2C%20and%20the%20median%20age%20was%2032%20years.%20Six%20patients%20were%20previously%20treated%20for%20TB%2C%20including%20four%20with%20first-line%20drugs.%20The%20most%20frequently%20affected%20site%20was%20the%20spine%20%28n%20%3D%2016%29.%20Bone%20and%20joint%20surgery%20were%20required%20in%2012%20patients.%20Twenty-one%20patients%20%2891%25%29%20successfully%20completed%20the%20treatment%20with%20a%20regimen%20containing%20a%20mean%20of%20four%20drugs%20%28range%2C%202%5Cu20136%29%20for%20a%20mean%20duration%20of%2020%20months%20%28range%2C%2013%5Cu201327%29.%20Overall%2C%20high%20rates%20of%20treatment%20success%20were%20achieved%20following%20WHO%20MDR-TB%20treatment%20guidelines%20and%20individualized%20patient%20management%20recommendations%20by%20the%20French%20National%20TB%20Consilium.%20However%2C%20the%20optimal%20combination%20of%20drugs%2C%20duration%20of%20treatment%20and%20role%20of%20surgery%20in%20the%20management%20of%20MDR-OATB%20remains%20to%20be%20determined.%22%2C%22date%22%3A%222022-6-14%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fmicroorganisms10061215%22%2C%22ISSN%22%3A%222076-2607%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9229793%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A21%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22NH7XCKNV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222022-05-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20G%26%23xFC%3Bnther%2C%20G.%2C%20Leu%2C%20C.%2C%20Cirillo%2C%20D.%2C%20Duarte%2C%20R.%2C%20Garcia-Basteiro%2C%20A.%20L.%2C%20Goletti%2C%20D.%2C%20Jankovic%2C%20M.%2C%20Kuksa%2C%20L.%2C%20Maurer%2C%20F.%20P.%2C%20M%26%23xE9%3Bcha%26%23xEF%3B%2C%20F.%2C%20Tiberi%2C%20S.%2C%20Leth%2C%20F.%20van%2C%20Veziris%2C%20N.%20and%20Lange%2C%20C.%20%282022%29.%20%3Cb%3ERifapentine%20access%20in%20Europe%3A%20growing%20concerns%20over%20key%20tuberculosis%20treatment%20component%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E59%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00388-2022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00388-2022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rifapentine%20access%20in%20Europe%3A%20growing%20concerns%20over%20key%20tuberculosis%20treatment%20component%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunar%22%2C%22lastName%22%3A%22G%5Cu00fcnther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Leu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%20L.%22%2C%22lastName%22%3A%22Garcia-Basteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delia%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mateja%22%2C%22lastName%22%3A%22Jankovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liga%22%2C%22lastName%22%3A%22Kuksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%20P.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22M%5Cu00e9cha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%20van%22%2C%22lastName%22%3A%22Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetLack%20of%20access%20to%20rifapentine%20in%20Europe%20denies%20patients%20optimal%20care%20for%20active%20tuberculosis%20and%20latent%20tuberculosis%20infection%2C%20and%20deprives%20healthcare%20providers%20of%20adequate%20tools%20to%20pursue%20tuberculosis%20control%20and%20elimination%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3jz85eh%22%2C%22date%22%3A%222022%5C%2F05%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00388-2022%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F59%5C%2F5%5C%2F2200388%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A23%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22DP27S3F7%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Ray%20et%20al.%22%2C%22parsedDate%22%3A%222022-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Ray%2C%20L.%20F.%2C%20Aubry%2C%20A.%2C%20Sougakoff%2C%20W.%2C%20Revest%2C%20M.%2C%20Robert%2C%20J.%2C%20Bonnet%2C%20I.%2C%20Veziris%2C%20N.%20and%20Morel%2C%20F.%20%282022%29.%20%3Cb%3EatpE%20Mutation%20in%20Mycobacterium%20tuberculosis%20Not%20Always%20Predictive%20of%20Bedaquiline%20Treatment%20Failure%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%201062%26%23x2013%3B1064%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2805.212517%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2805.212517%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22atpE%20Mutation%20in%20Mycobacterium%20tuberculosis%20Not%20Always%20Predictive%20of%20Bedaquiline%20Treatment%20Failure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%20Fournier%22%2C%22lastName%22%3A%22Le%20Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Revest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20the%20emergence%20of%20an%20atpE%20mutation%20in%20a%20clinical%20Mycobacterium%20tuberculosis%20strain.%20Genotypic%20and%20phenotypic%20bedaquiline%20susceptibility%20testing%20displayed%20variable%20results%20over%20time%20and%20ultimately%20were%20not%20predictive%20of%20treatment%20outcome.%20This%20observation%20highlights%20the%20limits%20of%20current%20genotypic%20and%20phenotypic%20methods%20for%20detection%20of%20bedaquiline%20resistance.%22%2C%22date%22%3A%222022-5%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2805.212517%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9045433%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-06T13%3A29%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22QDAG4PLL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Group%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGroup%2C%20A.%20S.%20T.%2C%20Georghiou%2C%20S.%20B.%2C%20Rodwell%2C%20T.%20C.%2C%20Korobitsyn%2C%20A.%2C%20Abbadi%2C%20S.%20H.%2C%20Ajbani%2C%20K.%2C%20Alffenaar%2C%20J.-W.%2C%20Alland%2C%20D.%2C%20Alvarez%2C%20N.%2C%20Andres%2C%20S.%2C%20Ardizzoni%2C%20E.%2C%20Aubry%2C%20A.%2C%20Baldan%2C%20R.%2C%20Ballif%2C%20M.%2C%20Barilar%2C%20I.%2C%20B%26%23xF6%3Bttger%2C%20E.%20C.%2C%20Chakravorty%2C%20S.%2C%20Claxton%2C%20P.%20M.%2C%20Cirillo%2C%20D.%20M.%2C%20Comas%2C%20I.%2C%20Coulter%2C%20C.%2C%20Denkinger%2C%20C.%20M.%2C%20Derendinger%2C%20B.%2C%20Desmond%2C%20E.%20P.%2C%20Steenwinkel%2C%20J.%20E.%20M.%20de%2C%20Dheda%2C%20K.%2C%20Diacon%2C%20A.%20H.%2C%20Dolinger%2C%20D.%20L.%2C%20Dooley%2C%20K.%20E.%2C%20Egger%2C%20M.%2C%20Ehsani%2C%20S.%2C%20Farhat%2C%20M.%20R.%2C%20Fattorini%2C%20L.%2C%20Finci%2C%20I.%2C%20Ray%2C%20L.%20F.%20L.%2C%20Furi%26%23xF3%3B%2C%20V.%2C%20Groenheit%2C%20R.%2C%20Gumbo%2C%20T.%2C%20Heysell%2C%20S.%20K.%2C%20Hillemann%2C%20D.%2C%20Hoffmann%2C%20H.%2C%20Hsueh%2C%20P.-R.%2C%20Hu%2C%20Y.%2C%20Huang%2C%20H.%2C%20Hussain%2C%20A.%2C%20Ismail%2C%20F.%2C%20Izumi%2C%20K.%2C%20Jagielski%2C%20T.%2C%20Johnson%2C%20J.%20L.%2C%20Kambli%2C%20P.%2C%20Kaniga%2C%20K.%2C%20Karunaratne%2C%20G.%20H.%20R.%20E.%2C%20Sharma%2C%20M.%20K.%2C%20Keller%2C%20P.%20M.%2C%20Kelly%2C%20E.%20C.%2C%20Kholina%2C%20M.%2C%20Kohli%2C%20M.%2C%20Kranzer%2C%20K.%2C%20Laurenson%2C%20I.%20F.%2C%20Limberis%2C%20J.%2C%20Lin%2C%20S.-Y.%20G.%2C%20Liu%2C%20Y.%2C%20L%26%23xF3%3Bpez-Gav%26%23xED%3Bn%2C%20A.%2C%20Lyander%2C%20A.%2C%20Machado%2C%20D.%2C%20Martinez%2C%20E.%2C%20Masood%2C%20F.%2C%20Mitarai%2C%20S.%2C%20Mvelase%2C%20N.%20R.%2C%20Niemann%2C%20S.%2C%20Nikolayevskyy%2C%20V.%2C%20Maurer%2C%20F.%20P.%2C%20Merker%2C%20M.%2C%20Miotto%2C%20P.%2C%20Omar%2C%20S.%20V.%2C%20Otto-Knapp%2C%20R.%2C%20Palaci%2C%20M.%2C%20Guti%26%23xE9%3Brrez%2C%20J.%20J.%20P.%2C%20Peacock%2C%20S.%20J.%2C%20Peloquin%2C%20C.%20A.%2C%20Perera%2C%20J.%2C%20Pierre-Audigier%2C%20C.%2C%20Pholwat%2C%20S.%2C%20Posey%2C%20J.%20E.%2C%20Prammananan%2C%20T.%2C%20Rigouts%2C%20L.%2C%20Robledo%2C%20J.%2C%20Rockwood%2C%20N.%2C%20Rodrigues%2C%20C.%2C%20Salfinger%2C%20M.%2C%20Schechter%2C%20M.%20C.%2C%20Seifert%2C%20M.%2C%20Sengstake%2C%20S.%2C%20Shinnick%2C%20T.%2C%20Shubladze%2C%20N.%2C%20Sintchenko%2C%20V.%2C%20Sirgel%2C%20F.%2C%20Somasundaram%2C%20S.%2C%20Sterling%2C%20T.%20R.%2C%20Spitaleri%2C%20A.%2C%20Streicher%2C%20E.%2C%20Supply%2C%20P.%2C%20Svensson%2C%20E.%2C%20Tagliani%2C%20E.%2C%20Tahseen%2C%20S.%2C%20Takaki%2C%20A.%2C%20Theron%2C%20G.%2C%20Torrea%2C%20G.%2C%20Deun%2C%20A.%20V.%2C%20Ingen%2C%20J.%20van%2C%20Rie%2C%20A.%20V.%2C%20Soolingen%2C%20D.%20van%2C%20Jr%2C%20R.%20V.%2C%20Venter%2C%20A.%2C%20Veziris%2C%20N.%2C%20Villellas%2C%20C.%2C%20Viveiros%2C%20M.%2C%20Warren%2C%20R.%2C%20Wen%2C%20S.%2C%20Werngren%2C%20J.%2C%20Wilkinson%2C%20R.%20J.%2C%20Yang%2C%20C.%2C%20Y%26%23x131%3Blmaz%2C%20F.%20F.%2C%20Zhang%2C%20T.%2C%20Zimenkov%2C%20D.%2C%20Ismail%2C%20N.%2C%20K%26%23xF6%3Bser%2C%20C.%20U.%20and%20Sch%26%23xF6%3Bn%2C%20T.%20%282022%29.%20%3Cb%3EUpdating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E59%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antimycobacterial%20Susceptibility%20Testing%22%2C%22lastName%22%3A%22Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophia%20B.%22%2C%22lastName%22%3A%22Georghiou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20C.%22%2C%22lastName%22%3A%22Rodwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexei%22%2C%22lastName%22%3A%22Korobitsyn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Said%20H.%22%2C%22lastName%22%3A%22Abbadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kanchan%22%2C%22lastName%22%3A%22Ajbani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Willem%22%2C%22lastName%22%3A%22Alffenaar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Alland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nataly%22%2C%22lastName%22%3A%22Alvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00f6nke%22%2C%22lastName%22%3A%22Andres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Ardizzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossella%22%2C%22lastName%22%3A%22Baldan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Barilar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20C.%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soumitesh%22%2C%22lastName%22%3A%22Chakravorty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%20M.%22%2C%22lastName%22%3A%22Claxton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20M.%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%5Cu00f1aki%22%2C%22lastName%22%3A%22Comas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chris%22%2C%22lastName%22%3A%22Coulter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20M.%22%2C%22lastName%22%3A%22Denkinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitta%22%2C%22lastName%22%3A%22Derendinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20P.%22%2C%22lastName%22%3A%22Desmond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jurriaan%20E.%20M.%20de%22%2C%22lastName%22%3A%22Steenwinkel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20H.%22%2C%22lastName%22%3A%22Diacon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20L.%22%2C%22lastName%22%3A%22Dolinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%20E.%22%2C%22lastName%22%3A%22Dooley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soudeh%22%2C%22lastName%22%3A%22Ehsani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%20R.%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lanfranco%22%2C%22lastName%22%3A%22Fattorini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iris%22%2C%22lastName%22%3A%22Finci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%20Fournier%20Le%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%22%2C%22lastName%22%3A%22Furi%5Cu00f3%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramona%22%2C%22lastName%22%3A%22Groenheit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tawanda%22%2C%22lastName%22%3A%22Gumbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20K.%22%2C%22lastName%22%3A%22Heysell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Doris%22%2C%22lastName%22%3A%22Hillemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harald%22%2C%22lastName%22%3A%22Hoffmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Po-Ren%22%2C%22lastName%22%3A%22Hsueh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi%22%2C%22lastName%22%3A%22Hu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hairong%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alamdar%22%2C%22lastName%22%3A%22Hussain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farzana%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyohiko%22%2C%22lastName%22%3A%22Izumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomasz%22%2C%22lastName%22%3A%22Jagielski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20L.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Priti%22%2C%22lastName%22%3A%22Kambli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kon%5Cu00e9%22%2C%22lastName%22%3A%22Kaniga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20H.%20R.%20Eranga%22%2C%22lastName%22%3A%22Karunaratne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meenu%20Kaushal%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M.%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellis%20C.%22%2C%22lastName%22%3A%22Kelly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margarita%22%2C%22lastName%22%3A%22Kholina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikashmi%22%2C%22lastName%22%3A%22Kohli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katharina%22%2C%22lastName%22%3A%22Kranzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%20F.%22%2C%22lastName%22%3A%22Laurenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%22%2C%22lastName%22%3A%22Limberis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.-Y.%20Grace%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yongge%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Gav%5Cu00edn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Lyander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faisal%22%2C%22lastName%22%3A%22Masood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Satoshi%22%2C%22lastName%22%3A%22Mitarai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nomonde%20R.%22%2C%22lastName%22%3A%22Mvelase%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladyslav%22%2C%22lastName%22%3A%22Nikolayevskyy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%20P.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Merker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaheed%20V.%22%2C%22lastName%22%3A%22Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralf%22%2C%22lastName%22%3A%22Otto-Knapp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mois%5Cu00e9s%22%2C%22lastName%22%3A%22Palaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Jos%5Cu00e9%20Palacios%22%2C%22lastName%22%3A%22Guti%5Cu00e9rrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharon%20J.%22%2C%22lastName%22%3A%22Peacock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20A.%22%2C%22lastName%22%3A%22Peloquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Perera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Pierre-Audigier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suporn%22%2C%22lastName%22%3A%22Pholwat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20E.%22%2C%22lastName%22%3A%22Posey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Therdsak%22%2C%22lastName%22%3A%22Prammananan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leen%22%2C%22lastName%22%3A%22Rigouts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaime%22%2C%22lastName%22%3A%22Robledo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neesha%22%2C%22lastName%22%3A%22Rockwood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camilla%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Max%22%2C%22lastName%22%3A%22Salfinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcos%20C.%22%2C%22lastName%22%3A%22Schechter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marva%22%2C%22lastName%22%3A%22Seifert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Sengstake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Shinnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%22%2C%22lastName%22%3A%22Shubladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vitali%22%2C%22lastName%22%3A%22Sintchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederick%22%2C%22lastName%22%3A%22Sirgel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sulochana%22%2C%22lastName%22%3A%22Somasundaram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Spitaleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Streicher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Supply%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Tagliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabira%22%2C%22lastName%22%3A%22Tahseen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akiko%22%2C%22lastName%22%3A%22Takaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Grant%22%2C%22lastName%22%3A%22Theron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Torrea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armand%20Van%22%2C%22lastName%22%3A%22Deun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakko%20van%22%2C%22lastName%22%3A%22Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annelies%20Van%22%2C%22lastName%22%3A%22Rie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dick%20van%22%2C%22lastName%22%3A%22Soolingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%20Vargas%22%2C%22lastName%22%3A%22Jr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amour%22%2C%22lastName%22%3A%22Venter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Villellas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Viveiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Warren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shu%27an%22%2C%22lastName%22%3A%22Wen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jim%22%2C%22lastName%22%3A%22Werngren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caie%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20Ferda%22%2C%22lastName%22%3A%22Y%5Cu0131lmaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tingting%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danila%22%2C%22lastName%22%3A%22Zimenkov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nazir%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%20U.%22%2C%22lastName%22%3A%22K%5Cu00f6ser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Sch%5Cu00f6n%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetInappropriately%20high%20breakpoints%20have%20resulted%20in%20systematic%20false-susceptible%20AST%20results%20to%20anti-TB%20drugs.%20MIC%2C%20PK%5C%2FPD%20and%20clinical%20outcome%20data%20should%20be%20combined%20when%20setting%20breakpoints%20to%20minimise%20the%20emergence%20and%20spread%20of%20antimicrobial%20resistance.%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3i43wb6%22%2C%22date%22%3A%222022%5C%2F04%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00166-2022%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F59%5C%2F4%5C%2F2200166%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A23%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22EDWVUW7S%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tunesi%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETunesi%2C%20S.%2C%20D%26%23xFB%3B%2C%20D.%20L.%2C%20Gualano%2C%20G.%2C%20Millet%2C%20J.-P.%2C%20Skrahin%2C%20A.%2C%20Bothamley%2C%20G.%2C%20Casas%2C%20X.%2C%20Goletti%2C%20D.%2C%20Lange%2C%20C.%2C%20Musso%2C%20M.%2C%20Palmieri%2C%20F.%2C%20Pourcher%2C%20V.%2C%20Rioux%2C%20C.%2C%20Skrahina%2C%20A.%2C%20Veziris%2C%20N.%2C%20Viatushka%2C%20D.%2C%20Jachym-Fr%26%23xE9%3Bchet%2C%20M.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3ECo-administration%20of%20treatment%20for%20rifampicin-resistant%20TB%20and%20chronic%20HCV%20infection%3A%20a%20TBnet%20and%20ESGMYC%20study%3C%5C%2Fb%3E.%20Journal%20of%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.03.004%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.03.004%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Co-administration%20of%20treatment%20for%20rifampicin-resistant%20TB%20and%20chronic%20HCV%20infection%3A%20a%20TBnet%20and%20ESGMYC%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gina%22%2C%22lastName%22%3A%22Gualano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan-Pau%22%2C%22lastName%22%3A%22Millet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aliaksandr%22%2C%22lastName%22%3A%22Skrahin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%22%2C%22lastName%22%3A%22Bothamley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Casas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delia%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Musso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrizio%22%2C%22lastName%22%3A%22Palmieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dzmitry%22%2C%22lastName%22%3A%22Viatushka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Jachym-Fr%5Cu00e9chet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-03-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jinf.2022.03.004%22%2C%22ISSN%22%3A%220163-4453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS016344532200130X%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T14%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22M3NEXJYZ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Migliori%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMigliori%2C%20G.%20B.%2C%20Wu%2C%20S.%20J.%2C%20Matteelli%2C%20A.%2C%20Zenner%2C%20D.%2C%20Goletti%2C%20D.%2C%20Ahmedov%2C%20S.%2C%20Al-Abri%2C%20S.%2C%20Allen%2C%20D.%20M.%2C%20Balcells%2C%20M.%20E.%2C%20Garcia-Basteiro%2C%20A.%20L.%2C%20Cambau%2C%20E.%2C%20Chaisson%2C%20R.%20E.%2C%20Chee%2C%20C.%20B.%20E.%2C%20Dalcolmo%2C%20M.%20P.%2C%20Denholm%2C%20J.%20T.%2C%20Erkens%2C%20C.%2C%20Esposito%2C%20S.%2C%20Farnia%2C%20P.%2C%20Friedland%2C%20J.%20S.%2C%20Graham%2C%20S.%2C%20Hamada%2C%20Y.%2C%20Harries%2C%20A.%20D.%2C%20Kay%2C%20A.%20W.%2C%20Kritski%2C%20A.%2C%20Manga%2C%20S.%2C%20Marais%2C%20B.%20J.%2C%20Menzies%2C%20D.%2C%20Ng%2C%20D.%2C%20Petrone%2C%20L.%2C%20Rendon%2C%20A.%2C%20Silva%2C%20D.%20R.%2C%20Schaaf%2C%20H.%20S.%2C%20Skrahina%2C%20A.%2C%20Sotgiu%2C%20G.%2C%20Thwaites%2C%20G.%2C%20Tiberi%2C%20S.%2C%20Tukvadze%2C%20N.%2C%20Zellweger%2C%20J.-P.%2C%20D%26%23x2019%3BAmbrosio%2C%20L.%2C%20Centis%2C%20R.%20and%20Ong%2C%20C.%20W.%20M.%20%282022%29.%20%3Cb%3EClinical%20standards%20for%20the%20diagnosis%2C%20treatment%20and%20prevention%20of%20TB%20infection%3C%5C%2Fb%3E.%20Int%20J%20Tuberc%20Lung%20Dis%20%3Ci%3E26%3C%5C%2Fi%3E%2C%20190%26%23x2013%3B205%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.21.0753%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.21.0753%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20standards%20for%20the%20diagnosis%2C%20treatment%20and%20prevention%20of%20TB%20infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20B.%22%2C%22lastName%22%3A%22Migliori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20J.%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Matteelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Zenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Ahmedov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Al-Abri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20E.%22%2C%22lastName%22%3A%22Balcells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Garcia-Basteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20E.%22%2C%22lastName%22%3A%22Chaisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20B.%20E.%22%2C%22lastName%22%3A%22Chee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Dalcolmo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22Denholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Erkens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Esposito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Farnia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20S.%22%2C%22lastName%22%3A%22Friedland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Graham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Hamada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Harries%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20W.%22%2C%22lastName%22%3A%22Kay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Manga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20J.%22%2C%22lastName%22%3A%22Marais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Petrone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rendon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20S.%22%2C%22lastName%22%3A%22Schaaf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sotgiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Thwaites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Tukvadze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-P.%22%2C%22lastName%22%3A%22Zellweger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22D%5Cu2019Ambrosio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Centis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%20M.%22%2C%22lastName%22%3A%22Ong%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%5CnTuberculosis%20%28TB%29%20preventive%20therapy%20%28TPT%29%20decreases%20the%20risk%20of%20developing%20TB%20disease%20and%20its%20associated%20morbidity%20and%20mortality.%20The%20aim%20of%20these%20clinical%20standards%20is%20to%20guide%20the%20assessment%2C%20management%20of%20TB%20infection%20%28TBI%29%20and%20implementation%20of%20TPT.%5Cn%5CnMETHODS%3A%5CnA%20panel%20of%20global%20experts%20in%20the%20field%20of%20TB%20care%20was%20identified%3B%2041%20participated%20in%20a%20Delphi%20process.%20A%205-point%20Likert%20scale%20was%20used%20to%20score%20the%20initial%20standards.%20After%20rounds%20of%20revision%2C%20the%20document%20was%20approved%20with%20100%25%20agreement.%5Cn%5CnRESULTS%3A%5CnEight%20clinical%20standards%20were%20defined%3A%20Standard%201%2C%20all%20individuals%20belonging%20to%20at-risk%20groups%20for%20TB%20should%20undergo%20testing%20for%20TBI%3B%20Standard%202%2C%20all%20individual%20candidates%20for%20TPT%20%28including%20caregivers%20of%20children%29%20should%20undergo%20a%20counselling%5C%2Fhealth%20education%20session%3B%20Standard%203%2C%20testing%20for%20TBI%3A%20timing%20and%20test%20of%20choice%20should%20be%20optimised%3B%20Standard%204%2C%20TB%20disease%20should%20be%20excluded%20prior%20to%20initiation%20of%20TPT%3B%20Standard%205%2C%20all%20candidates%20for%20TPT%20should%20undergo%20a%20set%20of%20baseline%20examinations%3B%20Standard%206%2C%20all%20individuals%20initiating%20TPT%20should%20receive%20one%20of%20the%20recommended%20regimens%3B%20Standard%207%2C%20all%20individuals%20who%20have%20started%20TPT%20should%20be%20monitored%3B%20Standard%208%2C%20a%20TBI%20screening%20and%20testing%20register%20should%20be%20kept%20to%20inform%20the%20cascade%20of%20care.%5Cn%5CnCONCLUSION%3A%5CnThis%20is%20the%20first%20consensus-based%20set%20of%20Clinical%20Standards%20for%20TBI.%20This%20document%20guides%20clinicians%2C%20programme%20managers%20and%20public%20health%20officers%20in%20planning%20and%20implementing%20adequate%20measures%20to%20assess%20and%20manage%20TBI.%22%2C%22date%22%3A%222022-3%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.21.0753%22%2C%22ISSN%22%3A%221027-3719%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8886963%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-05-26T21%3A18%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22MY9BQ8HY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guyeux%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuyeux%2C%20C.%2C%20Senelle%2C%20G.%2C%20Refr%26%23xE9%3Bgier%2C%20G.%2C%20Bretelle-Establet%2C%20F.%2C%20Cambau%2C%20E.%20and%20Sola%2C%20C.%20%282022%29.%20%3Cb%3EConnection%20between%20two%20historical%20tuberculosis%20outbreak%20sites%20in%20Japan%2C%20Honshu%2C%20by%20a%20new%20ancestral%20Mycobacterium%20tuberculosis%20L2%20sublineage%3C%5C%2Fb%3E.%20Epidemiology%20%26amp%3B%20Infection%20%3Ci%3E150%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS0950268822000048%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS0950268822000048%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Connection%20between%20two%20historical%20tuberculosis%20outbreak%20sites%20in%20Japan%2C%20Honshu%2C%20by%20a%20new%20ancestral%20Mycobacterium%20tuberculosis%20L2%20sublineage%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Guyeux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetan%22%2C%22lastName%22%3A%22Senelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guislaine%22%2C%22lastName%22%3A%22Refr%5Cu00e9gier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Bretelle-Establet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Sola%22%7D%5D%2C%22abstractNote%22%3A%22By%20gathering%20680%20publicly%20available%20Sequence%20Read%20Archives%20from%20isolates%20of%20Mycobacterium%20tuberculosis%20complex%20%28MTBC%29%20including%20190%20belonging%20to%20the%20lineage%202%20Beijing%2C%20and%20using%20an%20in-house%20bioinformatical%20pipeline%2C%20the%20TB-Annotator%2C%20that%20analyses%20more%20than%2050%20000%20characters%2C%20we%20describe%20herein%20a%20new%20L2%20sublineage%20from%2020%20isolates%20found%20in%20the%20Tochigi%20province%2C%20%28Japan%29%2C%20that%20we%20designate%20as%20asia%20ancestral%205%20%28AAnc5%29.%20These%20isolates%20harbour%20a%20number%20of%20specific%20criteria%20%2842%20SNPs%29%20and%20their%20intra-cluster%20pairwise%20distance%20suggests%20historical%20and%20not%20epidemiological%20transmission.%20These%20isolates%20harbour%20a%20mutation%20in%20rpoC%2C%20and%20do%20not%20fulfil%2C%20any%20of%20the%20modern%20Beijing%20lineage%20criteria%2C%20nor%20any%20of%20the%20other%20ancestral%20Beijing%20lineages%20described%20so%20far.%20Asia%20ancestral%205%20isolates%20do%20not%20possess%20mutT2%2058%20and%20ogt%2012%20characteristics%20of%20modern%20Beijing%2C%20but%20possess%20ancestral%20Beijing%20SNPs%20characteristics.%20By%20looking%20into%20the%20literature%2C%20we%20found%20a%20reference%20isolate%20ID381%2C%20described%20in%20Kobe%20and%20Osaka%20belonging%20to%20the%20%5Cu2018G3%5Cu2019%20group%2C%20sharing%2036%20out%20of%20the%2042%20specific%20SNPs%20found%20in%20AAnc5.%20We%20also%20assessed%20the%20intermediate%20position%20of%20the%20asia%20ancestral%204%20%28AAnc4%29%20sublineage%20recently%20described%20in%20Thailand%20and%20propose%20an%20improved%20classification%20of%20the%20L2%20that%20now%20includes%20AAnc4%20and%20AAnc5.%20By%20increasing%20the%20recruitment%20into%20TB-Annotator%20to%20around%203000%20genomes%20%28including%20642%20belonging%20to%20L2%29%2C%20we%20confirmed%20our%20results%20and%20discovered%20additional%20historical%20ancestral%20L2%20branches%20that%20remain%20to%20be%20investigated%20in%20more%20detail.%20We%20also%20present%2C%20in%20addition%2C%20some%20anthropological%20and%20historical%20data%20from%20Chinese%20and%20Japan%20history%20of%20tuberculosis%2C%20as%20well%20as%20from%20Korea%2C%20that%20could%20support%20our%20results%20on%20L2%20evolution.%20This%20study%20shows%20that%20the%20reconstruction%20of%20the%20early%20history%20of%20tuberculosis%20in%20Asia%20is%20likely%20to%20reveal%20complex%20patterns%20since%20its%20emergence.%22%2C%22date%22%3A%222022%5C%2Fed%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1017%5C%2FS0950268822000048%22%2C%22ISSN%22%3A%220950-2688%2C%201469-4409%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.cambridge.org%5C%2Fcore%5C%2Fjournals%5C%2Fepidemiology-and-infection%5C%2Farticle%5C%2Fconnection-between-two-historical-tuberculosis-outbreak-sites-in-japan-honshu-by-a-new-ancestral-mycobacterium-tuberculosis-l2-sublineage%5C%2F79482A3DD638BB99618B2CCDAA4EBC56%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-05-26T21%3A18%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22JN9GMQY9%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nyang%5Cu2019wa%20et%20al.%22%2C%22parsedDate%22%3A%222021-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ENyang%26%23x2019%3Bwa%2C%20B.%20T.%2C%20LaHood%2C%20A.%20N.%2C%20Mitnick%2C%20C.%20D.%20and%20Guglielmetti%2C%20L.%20%282021%29.%20%3Cb%3ETB%20research%20requires%20strong%20protections%2C%20innovation%2C%20and%20increased%20funding%20in%20response%20to%20COVID-19%3C%5C%2Fb%3E.%20Trials%20%3Ci%3E22%3C%5C%2Fi%3E%2C%201%26%23x2013%3B3%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-021-05331-4%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-021-05331-4%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22TB%20research%20requires%20strong%20protections%2C%20innovation%2C%20and%20increased%20funding%20in%20response%20to%20COVID-19%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20T.%22%2C%22lastName%22%3A%22Nyang%5Cu2019wa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20N.%22%2C%22lastName%22%3A%22LaHood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Mitnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021%5C%2F12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13063-021-05331-4%22%2C%22ISSN%22%3A%221745-6215%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ftrialsjournal.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs13063-021-05331-4%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A32%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22WSG27KUJ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonnet%20et%20al.%22%2C%22parsedDate%22%3A%222021-10-29%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBonnet%2C%20I.%2C%20Enouf%2C%20V.%2C%20Morel%2C%20F.%2C%20Ok%2C%20V.%2C%20Jaffr%26%23xE9%3B%2C%20J.%2C%20Jarlier%2C%20V.%2C%20Aubry%2C%20A.%2C%20Robert%2C%20J.%20and%20Sougakoff%2C%20W.%20%282021%29.%20%3Cb%3EA%20Comprehensive%20Evaluation%20of%20GeneLEAD%20VIII%20DNA%20Platform%20Combined%20to%20Deeplex%20Myc-TB%26%23xAE%3B%20Assay%20to%20Detect%20in%208%20Days%20Drug%20Resistance%20to%2013%20Antituberculous%20Drugs%20and%20Transmission%20of%20Mycobacterium%20tuberculosis%20Complex%20Directly%20From%20Clinical%20Samples%3C%5C%2Fb%3E.%20Front%20Cell%20Infect%20Microbiol%20%3Ci%3E11%3C%5C%2Fi%3E%2C%20707244%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcimb.2021.707244%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcimb.2021.707244%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Comprehensive%20Evaluation%20of%20GeneLEAD%20VIII%20DNA%20Platform%20Combined%20to%20Deeplex%20Myc-TB%5Cu00ae%20Assay%20to%20Detect%20in%208%20Days%20Drug%20Resistance%20to%2013%20Antituberculous%20Drugs%20and%20Transmission%20of%20Mycobacterium%20tuberculosis%20Complex%20Directly%20From%20Clinical%20Samples%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Enouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vichita%22%2C%22lastName%22%3A%22Ok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Jaffr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22The%20GeneLEAD%20VIII%20%28Diagenode%2C%20Belgium%29%20is%20a%20new%2C%20fully%20automated%2C%20sample-to-result%20precision%20instrument%20for%20the%20extraction%20of%20DNA%20and%20PCR%20detection%20of%20Mycobacterium%20tuberculosis%20complex%20%28MTBC%29%20directly%20from%20clinical%20samples.%20The%20Deeplex%20Myc-TB%5Cu00ae%20assay%20%28Genoscreen%2C%20France%29%20is%20a%20diagnostic%20kit%20based%20on%20the%20deep%20sequencing%20of%20a%2024-plexed%20amplicon%20mix%20allowing%20simultaneously%20the%20detection%20of%20resistance%20to%2013%20antituberculous%20%28antiTB%29%20drugs%20and%20the%20determination%20of%20spoligotype.%20We%20evaluated%20the%20performance%20of%20a%20strategy%20combining%20the%20both%20mentioned%20tools%20to%20detect%20directly%20from%20clinical%20samples%2C%20in%208%20days%2C%20MTBC%20and%20its%20resistance%20to%2013%20antiTB%20drugs%2C%20and%20identify%20potential%20transmission%20of%20strains%20from%20patient-to-patient.%20Using%20this%20approach%2C%20we%20screened%20112%20clinical%20samples%20%2865%20smear-negative%29%20and%2094%20MTBC%20cultured%20strains.%20The%20sensitivity%20and%20the%20specificity%20of%20the%20GeneLEAD%5C%2FDeeplex%20Myc-TB%20approach%20for%20MTBC%20detection%20were%2079.3%25%20and%20100%25%2C%20respectively.%20One%20hundred%20forty%20successful%20Deeplex%20Myc-TB%20results%20were%20obtained%20for%2046%20clinical%20samples%20and%2094%20strains%2C%20a%20total%20of%2085.4%25%20of%20which%20had%20a%20Deeplex%20Myc-TB%20susceptibility%20and%20resistance%20prediction%20consistent%20with%20phenotypic%20drug%20susceptibility%20testing%20%28DST%29.%20Importantly%2C%20the%20Deeplex%20Myc-TB%20assay%20was%20able%20to%20detect%20100%25%20of%20the%20multidrug-resistant%20%28MDR%29%20MTBC%20tested.%20The%20lowest%20concordance%20rates%20were%20for%20pyrazinamide%2C%20ethambutol%2C%20streptomycin%2C%20and%20ethionamide%20%2884.5%25%2C%2081.5%25%2C%2073%25%2C%20and%2055%25%2C%20respectively%29%20for%20which%20the%20determination%20of%20susceptibility%20or%20resistance%20is%20generally%20difficult%20with%20current%20tools.%20One%20of%20the%20main%20difficulties%20of%20Deeplex%20Myc-TB%20is%20to%20interpret%20the%20non-synonymous%20uncharacterized%20variants%20that%20can%20represent%20up%20to%2030%25%20of%20the%20detected%20single%20nucleotide%20variants.%20We%20observed%20a%20good%20level%20of%20concordance%20between%20Deeplex%20Myc-TB-spoligotyping%20and%20MIRU-VNTR%20despite%20a%20lower%20discriminatory%20power%20for%20spoligotyping.%20The%20median%20time%20to%20obtain%20complete%20results%20from%20clinical%20samples%20was%208%20days%20%28IQR%207%5Cu201313%29%20provided%20a%20high-throughput%20NGS%20sequencing%20platform%20was%20available.%20Our%20results%20highlight%20that%20the%20GeneLEAD%5C%2FDeeplex%20Myc-TB%20approach%20could%20be%20a%20breakthrough%20in%20rapid%20diagnosis%20of%20MDR%20TB%20in%20routine%20practice.%22%2C%22date%22%3A%222021-10-29%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffcimb.2021.707244%22%2C%22ISSN%22%3A%222235-2988%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8586210%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T23%3A11%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22WIAN9XI8%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20Ardizzoni%2C%20E.%2C%20Atger%2C%20M.%2C%20Baudin%2C%20E.%2C%20Berikova%2C%20E.%2C%20Bonnet%2C%20M.%2C%20Chang%2C%20E.%2C%20Cloez%2C%20S.%2C%20Coit%2C%20J.%20M.%2C%20Cox%2C%20V.%2C%20de%20Jong%2C%20B.%20C.%2C%20Delifer%2C%20C.%2C%20Do%2C%20J.%20M.%2C%20Tozzi%2C%20D.%20D.%20S.%2C%20Ducher%2C%20V.%2C%20Ferlazzo%2C%20G.%2C%20Gouillou%2C%20M.%2C%20Khan%2C%20A.%2C%20Khan%2C%20U.%2C%20Lachenal%2C%20N.%2C%20LaHood%2C%20A.%20N.%2C%20Lecca%2C%20L.%2C%20Mazmanian%2C%20M.%2C%20McIlleron%2C%20H.%2C%20Moschioni%2C%20M.%2C%20O%26%23x2019%3BBrien%2C%20K.%2C%20Okunbor%2C%20O.%2C%20Oyewusi%2C%20L.%2C%20Panda%2C%20S.%2C%20Patil%2C%20S.%20B.%2C%20Phillips%2C%20P.%20P.%20J.%2C%20Pichon%2C%20L.%2C%20Rupasinghe%2C%20P.%2C%20Rich%2C%20M.%20L.%2C%20Saluhuddin%2C%20N.%2C%20Seung%2C%20K.%20J.%2C%20Tamirat%2C%20M.%2C%20Trippa%2C%20L.%2C%20Cellamare%2C%20M.%2C%20Vel%26%23xE1%3Bsquez%2C%20G.%20E.%2C%20Wasserman%2C%20S.%2C%20Zimetbaum%2C%20P.%20J.%2C%20Varaine%2C%20F.%20and%20Mitnick%2C%20C.%20D.%20%282021%29.%20%3Cb%3EEvaluating%20newly%20approved%20drugs%20for%20multidrug-resistant%20tuberculosis%20%28endTB%29%3A%20study%20protocol%20for%20an%20adaptive%2C%20multi-country%20randomized%20controlled%20trial%3C%5C%2Fb%3E.%20Trials%20%3Ci%3E22%3C%5C%2Fi%3E%2C%20651%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-021-05491-3%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-021-05491-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluating%20newly%20approved%20drugs%20for%20multidrug-resistant%20tuberculosis%20%28endTB%29%3A%20study%20protocol%20for%20an%20adaptive%2C%20multi-country%20randomized%20controlled%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Ardizzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Atger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Baudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Berikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Cloez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Coit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20C.%22%2C%22lastName%22%3A%22de%20Jong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Delifer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20Dos%20Santos%22%2C%22lastName%22%3A%22Tozzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Ducher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Ferlazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Gouillou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Lachenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20N.%22%2C%22lastName%22%3A%22LaHood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Lecca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mazmanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22McIlleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Moschioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22O%5Cu2019Brien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Okunbor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Oyewusi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Panda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20B.%22%2C%22lastName%22%3A%22Patil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20P.%20J.%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Pichon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Rich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Saluhuddin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20J.%22%2C%22lastName%22%3A%22Seung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tamirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Trippa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cellamare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20E.%22%2C%22lastName%22%3A%22Vel%5Cu00e1squez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Wasserman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20J.%22%2C%22lastName%22%3A%22Zimetbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Varaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Mitnick%22%7D%5D%2C%22abstractNote%22%3A%22Background%5CnTreatment%20of%20multidrug-%5Cu00a0and%20rifampin-resistant%20tuberculosis%20%28MDR%5C%2FRR-TB%29%20is%20expensive%2C%20labour-intensive%2C%20and%20associated%20with%20substantial%20adverse%20events%20and%20poor%20outcomes.%20While%20most%20MDR%5C%2FRR-TB%20patients%20do%20not%20receive%20treatment%2C%20many%20who%20do%20are%20treated%20for%2018%20months%20or%20more.%20A%20shorter%20all-oral%20regimen%20is%20currently%20recommended%20for%20only%20a%20sub-set%20of%20MDR%5C%2FRR-TB.%20Its%20use%20is%20only%20conditionally%20recommended%20because%20of%20very%20low-quality%20evidence%20underpinning%20the%20recommendation.%20Novel%20combinations%20of%20newer%20and%20repurposed%20drugs%20bring%20hope%20in%20the%20fight%20against%20MDR%5C%2FRR-TB%2C%20but%20their%20use%20has%20not%20been%20optimized%20in%20all-oral%2C%20shorter%20regimens.%20This%20has%20greatly%20limited%20their%20impact%20on%20the%20burden%20of%20disease.%20There%20is%2C%20therefore%2C%20dire%20need%20for%20high-quality%20evidence%20on%20the%20performance%20of%20new%2C%20shortened%2C%20injectable-sparing%20regimens%20for%20MDR-TB%20which%20can%20be%20adapted%20to%20individual%20patients%20and%20different%20settings.%5Cn%5CnMethods%5CnendTB%20is%20a%20phase%20III%2C%20pragmatic%2C%20multi-country%2C%20adaptive%2C%20randomized%2C%20controlled%2C%20parallel%2C%20open-label%20clinical%20trial%20evaluating%20the%20efficacy%20and%20safety%20of%20shorter%20treatment%20regimens%20containing%20new%20drugs%20for%20patients%20with%20fluoroquinolone-susceptible%2C%20rifampin-resistant%20tuberculosis.%20Study%20participants%20are%20randomized%20to%20either%20the%20control%20arm%2C%20based%20on%20the%20current%20standard%20of%20care%20for%20MDR%5C%2FRR-TB%2C%20or%20to%20one%20of%20five%2039-week%20multi-drug%20regimens%20containing%20newly%20approved%20and%20repurposed%20drugs.%20Study%20participation%20in%20all%20arms%20lasts%20at%20least%2073%20and%20up%20to%20104%20weeks%20post-randomization.%20Randomization%20is%20response-adapted%20using%20interim%20Bayesian%20analysis%20of%20efficacy%20endpoints.%20The%20primary%20objective%20is%20to%20assess%20whether%20the%20efficacy%20of%20experimental%20regimens%20at%2073%20weeks%20is%20non-inferior%20to%20that%20of%20the%20control.%20A%20sample%20size%20of%20750%20patients%20across%206%20arms%20affords%20at%20least%2080%25%20power%20to%20detect%20the%20non-inferiority%20of%20at%20least%201%20%28and%20up%20to%203%29%20experimental%20regimens%2C%20with%20a%20one-sided%20alpha%20of%200.025%20and%20a%20non-inferiority%20margin%20of%2012%25%2C%20against%20the%20control%20in%20both%20modified%20intention-to-treat%20and%20per%20protocol%20populations.%5Cn%5CnDiscussion%5CnThe%20lack%20of%20a%20safe%20and%20effective%20regimen%20that%20can%20be%20used%20in%20all%20patients%20is%20a%20major%20obstacle%20to%20delivering%20appropriate%20treatment%20to%20all%20patients%20with%20active%20MDR%5C%2FRR-TB.%20Identifying%20multiple%20shorter%2C%20safe%2C%20and%20effective%20regimens%20has%20the%20potential%20to%20greatly%20reduce%20the%20burden%20of%20this%20deadly%20disease%20worldwide.%5Cn%5CnTrial%20registration%5CnClinicalTrials.gov%20Identifier%20NCT02754765.%20Registered%20on%2028%20April%202016%3B%20the%20record%20was%20last%20updated%20for%20study%20protocol%20version%203.3%2C%20on%2027%20August%202019.%22%2C%22date%22%3A%222021-9-25%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13063-021-05491-3%22%2C%22ISSN%22%3A%221745-6215%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8465691%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T14%3A16%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22BXKAYDV2%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Roelens%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-15%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERoelens%2C%20M.%2C%20Battista%20Migliori%2C%20G.%2C%20Rozanova%2C%20L.%2C%20Estill%2C%20J.%2C%20Campbell%2C%20J.%20R.%2C%20Cegielski%2C%20J.%20P.%2C%20Tiberi%2C%20S.%2C%20Palmero%2C%20D.%2C%20Fox%2C%20G.%20J.%2C%20Guglielmetti%2C%20L.%2C%20Sotgiu%2C%20G.%2C%20Brust%2C%20J.%20C.%20M.%2C%20Bang%2C%20D.%2C%20Lienhardt%2C%20C.%2C%20Lange%2C%20C.%2C%20Menzies%2C%20D.%2C%20Keiser%2C%20O.%20and%20Raviglione%2C%20M.%20%282021%29.%20%3Cb%3EEvidence-based%20Definition%20for%20Extensively%20Drug-Resistant%20Tuberculosis%3C%5C%2Fb%3E.%20Am%20J%20Respir%20Crit%20Care%20Med%20%3Ci%3E204%3C%5C%2Fi%3E%2C%20713%26%23x2013%3B722%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1164%5C%2Frccm.202009-3527OC%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1164%5C%2Frccm.202009-3527OC%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evidence-based%20Definition%20for%20Extensively%20Drug-Resistant%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maroussia%22%2C%22lastName%22%3A%22Roelens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Battista%20Migliori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liudmila%22%2C%22lastName%22%3A%22Rozanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janne%22%2C%22lastName%22%3A%22Estill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathon%20R.%22%2C%22lastName%22%3A%22Campbell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Peter%22%2C%22lastName%22%3A%22Cegielski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Domingo%22%2C%22lastName%22%3A%22Palmero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Greg%20J.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Sotgiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20C.%20M.%22%2C%22lastName%22%3A%22Brust%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didi%22%2C%22lastName%22%3A%22Bang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Lienhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dick%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Keiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Raviglione%22%7D%5D%2C%22abstractNote%22%3A%22Rationale%3A%20Until%202020%2C%20extensively%20drug-resistant%20tuberculosis%20%28XDR-TB%29%20was%20defined%20as%20TB%20with%20resistance%20to%20rifampicin%20and%20isoniazid%20%28multidrug-resistant%20TB%20%5BMDR-TB%5D%29%2C%20any%20fluoroquinolone%20%28FQ%29%2C%20and%20any%20second-line%20injectable%20drug%20%28SLID%29.%20In%202019%2C%20the%20World%20Health%20Organization%20issued%20new%20recommendations%20for%20treating%20patients%20with%20drug-resistant%20TB%2C%20substantially%20limiting%20the%20role%20of%20SLIDs%20in%20MDR-TB%20treatment%20and%20thus%20putting%20the%20definition%20of%20XDR-TB%20into%20question.%5Cn%5CnObjectives%3A%20To%20propose%20an%20up-to-date%20definition%20for%20XDR-TB.%5Cn%5CnMethods%3A%20We%20used%20a%20large%20data%20set%20to%20assess%20treatment%20outcomes%20for%20patients%20with%20MDR-TB%20exposed%20to%20any%20type%20of%20longer%20regimen.%20We%20included%20patients%20with%20bacteriologically%20confirmed%20MDR-TB%20and%20known%20FQ%20and%20SLID%20resistance%20results.%20We%20performed%20logistic%20regression%20to%20estimate%20the%20adjusted%20odds%20ratios%20%28aORs%29%20for%20an%20unfavorable%20treatment%20outcome%20%28failure%2C%20relapse%2C%20death%2C%20loss%20to%20follow-up%29%2C%20and%20estimates%20were%20stratified%20by%20the%20resistance%20pattern%20%28FQ%20and%5C%2For%20SLID%29%20and%20group%20A%20drug%20use%20%28moxifloxacin%5C%2Flevofloxacin%2C%20linezolid%2C%20and%5C%2For%20bedaquiline%29.%5Cn%5CnMeasurements%20and%20Main%20Results%3A%20We%20included%2011%2C666%20patients%20with%20MDR-TB%3B%204%2C653%20%2839.9%25%29%20had%20an%20unfavorable%20treatment%20outcome.%20Resistance%20to%20FQs%20increased%20the%20odds%20of%20an%20unfavorable%20treatment%20outcome%20%28aOR%2C%201.91%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%201.63%5Cu20132.23%29.%20Administration%20of%20bedaquiline%20and%5C%2For%20linezolid%20improved%20treatment%20outcomes%20regardless%20of%20resistance%20to%20FQs%20and%5C%2For%20SLIDs.%20Among%20patients%20with%20XDR-TB%2C%20compared%20with%20persons%20receiving%20no%20group%20A%20drug%2C%20aORs%20for%20an%20unfavorable%20outcome%20were%200.37%20%2895%25%20CI%2C%200.20%5Cu20130.69%29%20with%20linezolid%20only%2C%200.40%20%2895%25%20CI%2C%200.21%5Cu20130.77%29%20with%20bedaquiline%20only%2C%20and%200.21%20%2895%25%20CI%2C%200.12%5Cu20130.38%29%20with%20both.%5Cn%5CnConclusions%3A%20Our%20study%20supports%20a%20new%20definition%20of%20XDR-TB%20as%20MDR-TB%20and%20additional%20resistance%20to%20FQ%20plus%20bedaquiline%20and%5C%2For%20linezolid%20and%20helps%20assess%20the%20adequacy%20of%20this%20definition%20for%20surveillance%20and%20treatment%20choice.%22%2C%22date%22%3A%222021-09-15%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1164%5C%2Frccm.202009-3527OC%22%2C%22ISSN%22%3A%221073-449X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.atsjournals.org%5C%2Fdoi%5C%2F10.1164%5C%2Frccm.202009-3527OC%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A32%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22M3AU88AV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Veziris%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVeziris%2C%20N.%2C%20Bonnet%2C%20I.%2C%20Morel%2C%20F.%2C%20Guglielmetti%2C%20L.%2C%20Maitre%2C%20T.%2C%20Ray%2C%20L.%20F.%20L.%2C%20Sougakoff%2C%20W.%2C%20Robert%2C%20J.%20and%20Aubry%2C%20A.%20%282021%29.%20%3Cb%3EImpact%20of%20the%20revised%20definition%20of%20extensively%20drug-resistant%20tuberculosis%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E58%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00641-2021%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00641-2021%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20the%20revised%20definition%20of%20extensively%20drug-resistant%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%20Fournier%20Le%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22Extract%5CnRecently%2C%20the%20World%20Health%20Organization%20%28WHO%29%20has%20released%20a%20revised%20definition%20of%20extensively%20drug-resistant%20%28XDR%29%20tuberculosis%20%28TB%29%20that%20should%20be%20used%20for%20clinical%20and%20surveillance%20purposes%20starting%20from%201%20January%2C%202021%20%5B1%2C%202%5D.%20The%20previous%20definition%20of%20XDR-TB%20was%20TB%20that%20is%20resistant%20to%20any%20fluoroquinolone%20%28levofloxacin%20and%5C%2For%20moxifloxacin%29%20and%20to%20at%20least%20one%20of%20three%20second-line%20injectable%20drugs%20%28SLIs%3A%20capreomycin%2C%20kanamycin%20and%20amikacin%29%2C%20in%20addition%20to%20multidrug%20resistance.%20The%20revised%20definition%20is%3A%20TB%20caused%20by%20Mycobacterium%20tuberculosis%20strains%20that%20fulfil%20the%20definition%20of%20MDR%5C%2FRR-TB%20and%20which%20are%20also%20resistant%20to%20any%20fluoroquinolone%20and%20at%20least%20one%20additional%20group%20A%20drug.%20WHO%20group%20A%20drugs%20currently%20include%20fluoroquinolones%20%28levofloxacin%20or%20moxifloxacin%29%2C%20linezolid%20and%20bedaquiline.%20In%20addition%2C%20pre-XDR-TB%20is%20now%20a%20WHO-endorsed%20definition%2C%20identified%20as%20MDR%5C%2FRR-TB%20with%20any%20fluoroquinolone%20resistance.%20Although%20the%20previous%20definition%20of%20XDR-TB%20has%20proved%20to%20be%20predictive%20of%20poor%20treatment%20outcome%20%5B3%5D%2C%20the%202020%20update%20appears%20in%20line%20with%20recent%20changes%20of%20treatment%20regimens%20given%2C%20i.e.%20less%20frequent%20use%20of%20SLI%20in%20favour%20of%20the%20potent%20oral%20drugs%2C%20bedaquiline%20and%20linezolid.%20Moreover%2C%20a%20large%20meta-analysis%20failed%20to%20show%20an%20association%20between%20mortality%20reduction%20and%20SLI%20use%2C%20whereas%20this%20association%20was%20shown%20for%20bedaquiline%20and%20linezolid%20%5B4%5D.%20In%20this%20study%2C%20we%20aimed%20to%20measure%20retrospectively%20the%20impact%20of%20the%20revised%20definition%20on%20the%20epidemiology%20of%20XDR-TB%20in%20France.%5CnTweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetThe%20revised%20WHO%20definition%20of%20XDR-TB%20decreases%20the%20number%20of%20TB%20cases%20classified%20as%20such%2C%20and%20allows%20better%20focus%20on%20the%20most%20difficult%20to%20treat%20cases%20of%20TB%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3tgaXQA%22%2C%22date%22%3A%222021%5C%2F08%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00641-2021%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F58%5C%2F2%5C%2F2100641%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A29%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22Z9XZJ6DC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Starshinova%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EStarshinova%2C%20A.%2C%20Guglielmetti%2C%20L.%2C%20Rzhepishevska%2C%20O.%2C%20Ekaterincheva%2C%20O.%2C%20Zinchenko%2C%20Yu.%20and%20Kudlay%2C%20D.%20%282021%29.%20%3Cb%3EDiagnostics%20and%20management%20of%20tuberculosis%20and%20COVID-19%20in%20a%20patient%20with%20pneumothorax%20%28clinical%20case%29%3C%5C%2Fb%3E.%20J%20Clin%20Tuberc%20Other%20Mycobact%20Dis%20%3Ci%3E24%3C%5C%2Fi%3E%2C%20100259%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jctube.2021.100259%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jctube.2021.100259%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostics%20and%20management%20of%20tuberculosis%20and%20COVID-19%20in%20a%20patient%20with%20pneumothorax%20%28clinical%20case%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Starshinova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Rzhepishevska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Ekaterincheva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yu.%22%2C%22lastName%22%3A%22Zinchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Kudlay%22%7D%5D%2C%22abstractNote%22%3A%22The%20spread%20of%20COVID-19%20in%20countries%20with%20high%20and%20medium%20incidence%20of%20tuberculosis%20has%20led%20to%20an%20increased%20risk%20of%20COVID-19%20and%20tuberculosis%20co-infection%2C%20introducing%20new%20diagnostic%20and%20therapeutic%20challenges%20for%20the%20clinician.%20Hereby%20we%20describe%20a%20first%20case%20where%20tuberculosis%20and%20COVID-19%20were%20diagnosed%20concomitantly%20in%20a%20Russian%20patient%20with%20pneumothorax.%20We%20discuss%20the%20challenges%20associated%20with%20the%20diagnosis%20and%20treatment%20of%20tuberculosis%20during%20the%20COVID-19%20pandemic.%22%2C%22date%22%3A%222021-7-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jctube.2021.100259%22%2C%22ISSN%22%3A%222405-5794%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8245665%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-19T16%3A25%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22DKDYEURY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ok%20et%20al.%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EOk%2C%20V.%2C%20Aubry%2C%20A.%2C%20Morel%2C%20F.%2C%20Bonnet%2C%20I.%2C%20Robert%2C%20J.%20and%20Sougakoff%2C%20W.%20%282021%29.%20%3Cb%3ERapid%20Molecular%20Diagnosis%20of%20Tuberculosis%20and%20Its%20Resistance%20to%20Rifampicin%20and%20Isoniazid%20with%20Automated%20MDR%5C%2FMTB%20ELITe%20MGB%26%23xAE%3B%20Assay%3C%5C%2Fb%3E.%20Antibiotics%20%3Ci%3E10%3C%5C%2Fi%3E%2C%20797%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fantibiotics10070797%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fantibiotics10070797%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rapid%20Molecular%20Diagnosis%20of%20Tuberculosis%20and%20Its%20Resistance%20to%20Rifampicin%20and%20Isoniazid%20with%20Automated%20MDR%5C%2FMTB%20ELITe%20MGB%5Cu00ae%20Assay%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vichita%22%2C%22lastName%22%3A%22Ok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22The%20MDR%5C%2FMTB%20ELITe%20MGB%5Cu00ae%20kit%20%28ELITech%29%20carried%20on%20the%20ELITe%20InGenius%5Cu00ae%20platform%20is%20a%20new%20real-time%20PCR%20assay%20allowing%20automated%20extraction%20and%20detection%20of%20DNA%20of%20the%20Mycobacterium%20tuberculosis%20complex%20%28MTB%29%20and%20mutations%20in%20the%20rpoB%20and%20katG%20genes%20and%20inhA%20promoter%20region%20%28pro-inhA%29%20associated%20to%20resistance%20to%20rifampicin%20and%20isoniazid%2C%20the%20two%20markers%20of%20multidrug-resistant%20TB%20%28MDR%29.%20We%20assessed%20the%20performances%20of%20the%20test%20on%20a%20collection%20of%20strains%20%28n%20%3D%2054%29%20and%20a%20set%20of%20clinical%20samples%20%28n%20%3D%20242%29%20from%20routine%20practice%2C%20comparatively%20to%20TB%20diagnosis%20and%20genotypic%20drug%20susceptibility%20testing%20%28gDST%29%20as%20references.%20Regarding%20the%20242%20clinical%20samples%2C%20the%20sensitivity%20and%20specificity%20of%20MTB%20detection%20by%20ELITe%20were%2090.9%25%20and%2097.5%25%2C%20respectively.%20For%20the%20detection%20of%20resistance-conferring%20mutations%20on%20positive%20clinical%20samples%2C%20we%20observed%20perfect%20agreement%20with%20gDST%20for%20katG%20and%20pro-inhA%20%28%5Cu03ba%20%3D%201.0%29%20and%20two%20discordant%20results%20for%20rpoB%20%28%5Cu03ba%20%3D%200.82%29.%20Considering%20the%2054%20cultured%20strains%2C%20very%20good%20agreement%20with%20gDST%20was%20observed%20for%20the%20detection%20of%20the%2025%20distinct%20mutations%20in%20rpoB%2C%20katG%2C%20and%20pro-inhA%2C%20%28%5Cu03ba%20%3D%200.95%2C%200.88%2C%20and%200.95%2C%20respectively%29.%20In%20conclusion%2C%20the%20automated%20MDR%5C%2FMTB%20ELITe%20MGB%5Cu00ae%20assay%20shows%20great%20promise%20and%20appears%20to%20be%20a%20valuable%20tool%20for%20rapid%20detection%20of%20pre-MDR-%20and%20MDR-TB%20directly%20from%20clinical%20specimens.%22%2C%22date%22%3A%222021%5C%2F7%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fantibiotics10070797%22%2C%22ISSN%22%3A%222079-6382%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2079-6382%5C%2F10%5C%2F7%5C%2F797%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A27%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22N2BKBBDI%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hewison%20and%20Guglielmetti%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHewison%2C%20C.%20and%20Guglielmetti%2C%20L.%20%282021%29.%20%3Cb%3ECardiac%20safety%20of%20multidrug-resistant%20tuberculosis%20treatment%3A%20moving%20towards%20individualised%20monitoring%3C%5C%2Fb%3E.%20Lancet%20Infect%20Dis%20%3Ci%3E21%3C%5C%2Fi%3E%2C%20894%26%23x2013%3B895%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2820%2930836-7%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2820%2930836-7%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cardiac%20safety%20of%20multidrug-resistant%20tuberculosis%20treatment%3A%20moving%20towards%20individualised%20monitoring%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Hewison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS1473-3099%2820%2930836-7%22%2C%22ISSN%22%3A%221474-4457%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A33%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22D6F5BYLH%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20and%20Varaine%22%2C%22parsedDate%22%3A%222021-06-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%20and%20Varaine%2C%20F.%20%282021%29.%20%3Cb%3EThe%20coming-of-age%20of%20bedaquiline%3A%20a%20tale%20with%20an%20open%20ending%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E57%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00066-2021%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00066-2021%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20coming-of-age%20of%20bedaquiline%3A%20a%20tale%20with%20an%20open%20ending%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Varaine%22%7D%5D%2C%22abstractNote%22%3A%22Extract%5CnBedaquiline%20can%20probably%20be%20considered%20the%20biggest%20breakthrough%20in%20tuberculosis%20drug%20development%20of%20the%20past%20decades.%20The%20first%20compound%20of%20a%20new%20anti-tuberculosis%20drug%20class%2C%20diarylquinolines%2C%20bedaquiline%20binds%20the%20mycobacterial%20ATP%20synthase%2C%20inducing%20major%20conformational%20changes%20and%20ultimately%20impacting%20the%20bacterial%20respiration%20pathway%20%5B1%2C%202%5D.%20After%20being%20developed%20in%202005%20%5B3%5D%2C%20bedaquiline%20showed%20promising%20results%20in%20phase%20II%20trials%20%5B4%2C%205%5D%2C%20and%20was%20granted%20accelerated%20approval%20in%202012%20by%20the%20US%20Food%20and%20Drug%20Administration%20%28FDA%29%20and%20conditional%20approval%20in%202014%20by%20the%20European%20Medicines%20Agency.%20In%20the%20following%20years%2C%20the%20access%20to%20bedaquiline%20has%20progressively%20increased%2C%20from%20compassionate%20to%20programmatic%20use%20%5B6%2C%207%5D%2C%20although%20at%20an%20insufficient%20pace.%20Between%20July%202015%20and%20December%202019%2C%2051%20098%20patients%20received%20bedaquiline%20worldwide%3A%20although%20remarkable%2C%20this%20figure%20only%20represents%2011%25%20of%20those%20who%20are%20estimated%20to%20need%20it%20according%20to%20the%20most%20recent%20recommendations%20by%20the%20World%20Health%20Organization%20%28WHO%29%20%5B8%5D.%5CnTweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetFuture%20strategic%20choices%20in%20the%20clinical%20development%20of%20bedaquiline%20should%20be%20guided%20by%20the%20need%20to%20generate%20high-quality%20evidence%20and%20ultimately%20improve%20outcomes%20of%20tuberculosis%20treatment%2C%20while%20preventing%20the%20emergence%20of%20drug%20resistance%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3iAOCZr%22%2C%22date%22%3A%222021%5C%2F06%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00066-2021%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F57%5C%2F6%5C%2F2100066%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A28%3A43Z%22%7D%7D%2C%7B%22key%22%3A%2295VRF8CW%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22World%20Health%20Organisation%22%2C%22parsedDate%22%3A%222021-05-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWorld%20Health%20Organisation%20%282021%29.%20Technical%20Report%20on%20critical%20concentrations%20for%20drug%20susceptibility%20testing%20of%20isoniazid%20and%20the%20rifamycins%20%28rifampicin%2C%20rifabutin%20and%20rifapentine%29%2C%20WHO%2C%20Geneva%2C%20URL%3A%20%3Ca%20target%3D%27_blank%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.who.int%5C%2Fpublications%5C%2Fi%5C%2Fitem%5C%2Ftechnical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-%28rifampicin-rifabutin-and-rifapentine%29%27%3Ehttps%3A%5C%2F%5C%2Fwww.who.int%5C%2Fpublications%5C%2Fi%5C%2Fitem%5C%2Ftechnical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-%28rifampicin-rifabutin-and-rifapentine%29%3C%5C%2Fa%3E%20%5BAccessed%20March%202022%5D.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22report%22%2C%22title%22%3A%22Technical%20Report%20on%20critical%20concentrations%20for%20drug%20susceptibility%20testing%20of%20isoniazid%20and%20the%20rifamycins%20%28rifampicin%2C%20rifabutin%20and%20rifapentine%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22World%20Health%20Organisation%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22reportNumber%22%3A%22978-92-4-001728-3%22%2C%22reportType%22%3A%22%22%2C%22institution%22%3A%22WHO%22%2C%22date%22%3A%2205%5C%2F02%5C%2F2021%22%2C%22language%22%3A%22Anglais%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.who.int%5C%2Fpublications%5C%2Fi%5C%2Fitem%5C%2Ftechnical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-%28rifampicin-rifabutin-and-rifapentine%29%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T23%3A20%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22I4RV4A3G%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Guglielmetti%2C%20L.%20and%20Veziris%2C%20N.%20%282021%29.%20%3Cb%3EDefining%20optimal%20fluoroquinolone%20exposure%20against%20Mycobacterium%20tuberculosis%3A%20contribution%20of%20murine%20studies%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E57%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.04315-2020%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.04315-2020%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Defining%20optimal%20fluoroquinolone%20exposure%20against%20Mycobacterium%20tuberculosis%3A%20contribution%20of%20murine%20studies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22Extract%5CnWe%20read%20with%20interest%20the%20research%20letter%20published%20by%20Davies%20Forsman%20et%20al.%20%5B1%5D%20in%20the%20European%20Respiratory%20Journal.%20The%20authors%20determined%20the%20proportion%20of%20multidrug-resistant%20tuberculosis%20patients%20treated%20with%20moxifloxacin%20or%20levofloxacin%20who%20attained%20an%20optimal%20exposure%20for%20these%20drugs.%20The%20target%20exposure%20corresponded%20to%20the%20area%20under%20the%20curve%20%28AUC0%5Cu201324h%29%5C%2Fminimal%20inhibitory%20concentration%20%28MIC%29%20ratio%20generating%20the%20optimal%20bactericidal%20activity.%20The%20authors%20based%20their%20calculations%20on%20the%20AUC0%5Cu201324h%5C%2FMIC%20ratio%20measured%20in%20a%20preclinical%20model%20called%20Hollow%20Fiber%20System%20%28HFS%29%2C%20an%20in%20vitro%20model%20used%20to%20assess%20anti-tuberculosis%20activity%20of%20candidate%20drugs.%20Based%20on%20this%20model%2C%20they%20reported%20that%20the%20target%20ratio%20was%20reached%20in%20only%20half%20of%20patients%20receiving%20moxifloxacin%2C%20and%20in%20none%20of%20those%20receiving%20levofloxacin.%5CnTweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetThe%20proportion%20of%20TB%20patients%20attaining%20the%20fluoroquinolone%20target%20exposure%2C%20as%20defined%20by%20in%20vitro%20models%2C%20is%20very%20low%20in%20clinical%20practice%3B%20however%2C%20it%20would%20be%20even%20smaller%20if%20the%20target%20AUC%5C%2FMIC%20ratios%20were%20calculated%20in%20murine%20models%20of%20tuberculosis%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F2Wg8K8H%22%2C%22date%22%3A%222021%5C%2F04%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.04315-2020%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F57%5C%2F4%5C%2F2004315%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A29%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22UG9CJEM5%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mohamed%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMohamed%2C%20S.%2C%20K%26%23xF6%3Bser%2C%20C.%20U.%2C%20Salfinger%2C%20M.%2C%20Sougakoff%2C%20W.%20and%20Heysell%2C%20S.%20K.%20%282021%29.%20%3Cb%3ETargeted%20next-generation%20sequencing%3A%20a%20Swiss%20army%20knife%20for%20mycobacterial%20diagnostics%3F%3C%5C%2Fb%3E%20European%20Respiratory%20Journal%20%3Ci%3E57%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.04077-2020%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.04077-2020%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Targeted%20next-generation%20sequencing%3A%20a%20Swiss%20army%20knife%20for%20mycobacterial%20diagnostics%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sagal%22%2C%22lastName%22%3A%22Mohamed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%20U.%22%2C%22lastName%22%3A%22K%5Cu00f6ser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Max%22%2C%22lastName%22%3A%22Salfinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20K.%22%2C%22lastName%22%3A%22Heysell%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetLike%20a%20multifunctional%20Swiss%20army%20knife%2C%20Deeplex%20offers%20unprecedented%20versatility%20directly%20from%20the%20clinical%20sample%20and%20represents%20a%20welcome%20addition%20to%20the%20diagnostic%20and%20epidemiological%20toolbox%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F38s6ukF%22%2C%22date%22%3A%222021%5C%2F03%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.04077-2020%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F57%5C%2F3%5C%2F2004077%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A27%3A49Z%22%7D%7D%2C%7B%22key%22%3A%225JB2PK4Y%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sch%5Cu00f6n%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESch%26%23xF6%3Bn%2C%20T.%2C%20Werngren%2C%20J.%2C%20Machado%2C%20D.%2C%20Borroni%2C%20E.%2C%20Wijkander%2C%20M.%2C%20Lina%2C%20G.%2C%20Mouton%2C%20J.%2C%20Matuschek%2C%20E.%2C%20Kahlmeter%2C%20G.%2C%20Giske%2C%20C.%2C%20Santin%2C%20M.%2C%20Cirillo%2C%20D.%20M.%2C%20Viveiros%2C%20M.%20and%20Cambau%2C%20E.%20%282021%29.%20%3Cb%3EMulticentre%20testing%20of%20the%20EUCAST%20broth%20microdilution%20reference%20method%20for%20MIC%20determination%20on%20Mycobacterium%20tuberculosis%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20%3Ci%3E27%3C%5C%2Fi%3E%2C%20288.e1-288.e4%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2020.10.019%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2020.10.019%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multicentre%20testing%20of%20the%20EUCAST%20broth%20microdilution%20reference%20method%20for%20MIC%20determination%20on%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Sch%5Cu00f6n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jim%22%2C%22lastName%22%3A%22Werngren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuele%22%2C%22lastName%22%3A%22Borroni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Wijkander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Lina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Mouton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erika%22%2C%22lastName%22%3A%22Matuschek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunnar%22%2C%22lastName%22%3A%22Kahlmeter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Giske%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Santin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20Maria%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Viveiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-02-01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2020.10.019%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.clinicalmicrobiologyandinfection.com%5C%2Farticle%5C%2FS1198-743X%2820%2930650-9%5C%2Ffulltext%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-10T10%3A52%3A38Z%22%7D%7D%5D%7D
Godefroy, N., Monsel, G., Jauréguiberry, S., Henry, B., Véziris, N., Aubry, A., Robert, J., Jachym, M., Caumes, E. and Pourcher, V. (2024). Lessons learned from treating drug-resistant TB and how to apply these to drug-susceptible TB. int j tuberc lung dis 28, 357–359, http://doi.org/10.5588/ijtld.23.0548.
Veziris, N., Aubry, A., Bonnet, I., Petersen, T., Poignon, C., Gydé, E., Guglielmetti, L. and Robert, J. (2024). Actualités sur la tuberculose à bacilles multirésistants aux antibiotiques et ses nouveaux traitements. Bull Épid Hebdo 127–131, URL: http://beh.santepubliquefrance.fr/beh/2024/6-7/2024_6-7_4.html [Accessed March 2024].
Friesen, I., Saluzzo, F., Groenheit, R., Aubry, A., Anthony, R., Niemann, S., Mathys, V., Cirillo, D. M., Indra, A., Mathys, V., Atanasova, Y., Obrovac, M., Žmak, L., Pieridou, D., Dvořákov, V., Troels Lillebæk, Kummik, T., Klaos, K., Soini, H., Haanperä-Heikkinen, M., Mentula, S., Jérôme, R., Cambau, E., Niemann, S., Panayotis, I., Papaventsis, D., Bakos, Á., Szél, V., Lőrinczi, L. K., Fitzgibbon, M., Boyle, B., Cirillo, D. M., Giannoni, F., Pole, I., Norvaiša, I., Vasiliauskaite, L., Perrin, M., Deguara, C., Anthony, R., Mengshoel, A. T., Augustynowicz-Kopeć, E., Macedo, R., Coriu, R. M., Porvaznik, I., Klemen, Š., Herrera-León, L., Groenheit, R. and Werngren, J. (2024). Re: “Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe” by Lange et al. Clinical Microbiology and Infection S1198743X24002775, http://doi.org/10.1016/j.cmi.2024.06.001.
Maitre, T., Baulard, A., Aubry, A. and Veziris, N. (2024). Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis. Infectious Diseases Now 54, 104807, http://doi.org/10.1016/j.idnow.2023.104807.
Maitre, T., Guglielmetti, L., Robert, J., Aubry, A. and Veziris, N. (2024). Avancées dans l’antibiothérapie de la tuberculose. Rev Prat 74, 239–244.
Campbell, J. R., Brode, S. K., Barry, P., Bastos, M. L., Bonnet, M., Guglielmetti, L., Kempker, R., Klimuk, D., Laborín, R. L., Milanov, V., Singla, R., Skrahina, A., Trajman, A., Van Der Werf, T. S., Viiklepp, P. and Menzies, D. (2023). Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis. Thorax thorax-2023-220249, http://doi.org/10.1136/thorax-2023-220249.
Du Cros, P., Greig, J., Alffenaar, J.-W. C., Cross, G. B., Cousins, C., Berry, C., Khan, U., Phillips, P. P. J., Velásquez, G. E., Furin, J., Spigelman, M., Denholm, J. T., Thi, S. S., Tiberi, S., Huang, G. K. L., Marks, G. B., Turkova, A., Guglielmetti, L., Chew, K. L., Nguyen, H. T., Ong, C. W. M., Brigden, G., Singh, K. P., Motta, I., Lange, C., Seddon, J. A., Nyang’wa, B.-T., Maug, A. K. J., Gler, M. T., Dooley, K. E., Quelapio, M., Tsogt, B., Menzies, D., Cox, V., Upton, C. M., Skrahina, A., McKenna, L., Horsburgh, C. R., Dheda, K. and Marais, B. J. (2023). Standards for clinical trials for treating TB. int j tuberc lung dis 27, 885–898, http://doi.org/10.5588/ijtld.23.0341.
Patil, S. B., Tamirat, M., Khazhidinov, K., Ardizzoni, E., Atger, M., Austin, A., Baudin, E., Bekhit, M., Bektasov, S., Berikova, E., Bonnet, M., Caboclo, R., Chaudhry, M., Chavan, V., Cloez, S., Coit, J., Coutisson, S., Dakenova, Z., De Jong, B. C., Delifer, C., Demaisons, S., Do, J. M., Dos Santos Tozzi, D., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, U., Kunda, M., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moreau, M., Moschioni, M., Nahid, P., Osso, E., Oyewusi, L., Panda, S., Pâquet, A., Thuong Huu, P., Pichon, L., Rich, M. L., Rupasinghe, P., Salahuddin, N., Sanchez Garavito, E., Seung, K. J., Velásquez, G. E., Vallet, M., Varaine, F., Yuya-Septoh, F. J., Mitnick, C. D. and Guglielmetti, L. (2023). Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Trials 24, 773, http://doi.org/10.1186/s13063-023-07701-6.
Sahal, M. R., Senelle, G., La, K., Panda, T. W., Taura, D. W., Guyeux, C., Cambau, E. and Sola, C. (2023). Mycobacterium tuberculosis complex drug-resistance, phylogenetics, and evolution in Nigeria: Comparison with Ghana and Cameroon Ed. Rayner, S. PLoS Negl Trop Dis 17, e0011619, http://doi.org/10.1371/journal.pntd.0011619.
Günther, G., Guglielmetti, L., Leu, C., van Leth, F. and Lange, C. (2023). Relative cost of multidrug-resistant TB medicines in Europe. The International Journal of Tuberculosis and Lung Disease 27, 341–344, http://doi.org/10.5588/ijtld.23.0026.
Campbell, J. R., Chan, E. D., Anderson, L. F., Bonnet, M., Brode, S. K., Cegielski, J. P., Guglielmetti, L., Singla, R., Fox, G. J., Skrahina, A., Rodrigues, D., Kuksa, L., Viiklepp, P. and Menzies, D. (2023). Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes. The International Journal of Tuberculosis and Lung Disease 27, 338–340, http://doi.org/10.5588/ijtld.22.0678.
Guthmann, J.-P., Fraisse, P., Bonnet, I. and Robert, J. (2023). Active tuberculosis screening among the displaced population fleeing Ukraine, France, February to October 2022. Eurosurveillance 28, http://doi.org/10.2807/1560-7917.ES.2023.28.12.2300155.
Aubry, A. and Veziris, N. (2023). La tuberculose, l’une des plus anciennes maladies infectieuses : quelles avancées récentes majeures ? Med Sci (Paris) 39, 203–204, http://doi.org/10.1051/medsci/2023054.
Masini, T., Furin, J., Udwadia, Z. and Guglielmetti, L. (2023). Optimal management of drug-resistant tuberculosis: Can India lead the way? Indian Journal of Medical Research 157, 220, http://doi.org/10.4103/ijmr.ijmr_300_23.
Domínguez, José, Boeree, M. J., Cambau, E., Chesov, D., Conradie, F., Cox, V., Dheda, K., Dudnyk, A., Farhat, M. R., Gagneux, S., Grobusch, M. P., Gröschel, M. I., Guglielmetti, L., Kontsevaya, I., Lange, B., van Leth, F., Lienhardt, C., Mandalakas, Anna M, Maurer, F. P., Merker, M., Miotto, P., Molina-Moya, B., Morel, F., Niemann, S., Veziris, N., Whitelaw, A., Horsburgh, Charles R, Lange, C., Domínguez, Jose, Boeree, M. J., Cambau, E., Chesov, D., Conradie, F., Cox, V., Dheda, K., Dudnyk, A., Farhat, M. R., Gagneux, S., Grobusch, M. P., Gröschel, M. I., Guglielmetti, L., Kontsevaya, I., Lange, B., van Leth, F., Lienhardt, C., Mandalakas, Anna Maria, Maurer, F., Merker, M., Miotto, P., Molina-Moya, B., Morel, F., Niemann, S., Veziris, N., Whitelaw, A., Horsburgh, Charles Robert and Lange, C. (2023). Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. The Lancet Infectious Diseases, http://doi.org/10.1016/S1473-3099(22)00875-1.
Barbier, E., Fouchet, T., Hartmann, A., Cambau, E., Mougari, F., Dubois, C., Lubetzki, M. and Rochelet, M. (2023). Rapid electrochemical detection of Mycobacterium tuberculosis in sputum by measuring Ag85 activity with disposable carbon sensors. Talanta 253, 123927, http://doi.org/10.1016/j.talanta.2022.123927.
Khan, U. and Guglielmetti, L. (2023). Tailored TPT for drug-resistant TB - promoting equity and access to optimal care. Int J Tuberc Lung Dis 27, 89b–890, http://doi.org/10.5588/ijtld.22.0538.
Günther, G., Guglielmetti, L., Leu, C., Lange, C., van Leth, F., Hasan Hafizi, Khachatryan, N., Aroyan, H., Kabasakalyan, E., Knappik, M., Skrahina, A., Klimuk, D., Nikolenka, A., Muylle, I., Milanov, V., Velkovska, D., Tarinska, N., Bachiyska, E., Jankovic, M., Pieridou, D., Adamide, T., Nicolaou, N., Vasakova, M., Sukholytka, M., Kopeckà, E., Folkvardsen, D. B., Svensson, E., Danilovits, M., Kummik, T., Vasankari, T., Fréchet-Jachym, M., Nahmiash, A., Togonidze, T., Avaliani, Z., Kinkladze, I., Aspindzelashvili, R., Bichashvili, T., Losaberidze, G., Merabishvili, T., Kalsdorf, B., Manika, K., Tsiakitzis, K., Bakos, A., Ægisdóttir, T. R., Michelsen, G. S., Karlsdóttir, K., McLaughlin, A.-M., Fitzgibbon, M., Chemtob, D., Codecasa, L. R., Ferrarese, M., Torri, S., Gjocaj, M., Kuksa, L., Davidaviciene, E., Wirtz, G., Perrin, M., Asciak, A. P., Chesov, D., de Lange, W., Akkerman, O., Poposka, B. I., Mack, U., Jensenius, M., Kvalvik, L., Mengshoel, A. T., Kruczak, K., Duarte, R., Ribeiro, N., Ibraim, E., Kaluzhenina, A., Barkanova, O., Pesut, D., Solovic, I., Svetina, P., Souza-Galvão, M.-L. de, Millet, J.-P., Casas, X., Vives, M., Bruchfeld, J., Dalemo, P., Jonsson, J., Aeschbacher, K., Keller, P., Özkara, S., Tiberi, S., Chen, C., Terleeva, Y. and Dudnyk, A. (2023). Availability and costs of medicines for the treatment of tuberculosis in Europe. Clinical Microbiology and Infection 29, 77–84, http://doi.org/10.1016/j.cmi.2022.07.026.
Senelle, G., Sahal, M. R., La, K., Billard-Pomares, T., Marin, J., Mougari, F., Bridier-Nahmias, A., Carbonnelle, E., Cambau, E., Refrégier, G., Guyeux, C. and Sola, C. (2023). Towards the reconstruction of a global TB history using a new pipeline “TB-Annotator". Tuberculosis 143, 102376, http://doi.org/10.1016/j.tube.2023.102376.
Motta, I., Boeree, M., Chesov, D., Dheda, K., Günther, G., Horsburgh, C. R., Kherabi, Y., Lange, C., Lienhardt, C., McIlleron, H. M., Paton, N. I., Stagg, H. R., Thwaites, G., Udwadia, Z., Van Crevel, R., Velásquez, G. E., Wilkinson, R. J., Guglielmetti, L., Motta, I., Kherabi, Y., Van Crevel, R. and Guglielmetti, L. (2023). Recent advances in the treatment of tuberculosis. Clinical Microbiology and Infection S1198743X23003397, http://doi.org/10.1016/j.cmi.2023.07.013.
Holmgaard, F. B., Guglielmetti, L., Lillebaek, T., Andersen, Å. B., Wejse, C. and Dahl, V. N. (2022). Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Clin Infect Dis ciac876, http://doi.org/10.1093/cid/ciac876.
Wetzstein, N., Drummer, A.-P., Bockey, A., Herrmann, E., Küpper-Tetzel, C. P., Graf, C., Koch, B., Goetsch, U., Vehreschild, M. J. G. T., Guglielmetti, L., Lange, B., Wichelhaus, T. A. and Stephan, C. (2022). Occurrence of extrapulmonary tuberculosis is associated with geographical origin: spatial characteristics of the Frankfurt TB cohort 2013–2018. Infection, http://doi.org/10.1007/s15010-022-01921-9.
Kherabi, Y., Tunesi, S., Kay, A. and Guglielmetti, L. (2022). Preventive Therapy for Contacts of Drug-Resistant Tuberculosis. Pathogens 11, 1189, http://doi.org/10.3390/pathogens11101189.
Khan, U. and Guglielmetti, L. (2022). Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB. The International Journal of Tuberculosis and Lung Disease 26, 900–901, http://doi.org/10.5588/ijtld.22.0328.
Kherabi, Y., Fréchet-Jachym, M., Rioux, C., Yazdanpanah, Y., Méchaï, F., Pourcher, V., Robert, J. and Guglielmetti, L. (2022). Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019. Emerg Infect Dis 28, 1796–1804, http://doi.org/10.3201/eid2809.220458.
De Castro, N., Mechaï, F., Bachelet, D., Canestri, A., Joly, V., Vandenhende, M., Boutoille, D., Kerjouan, M., Veziris, N., Molina, J. M., Grall, N., Tattevin, P., Laouénan, C., Yazdanpanah, Y. and for the FAST TB Study Group (2022). Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB). Open Forum Infectious Diseases 9, ofac353, http://doi.org/10.1093/ofid/ofac353.
Kraef, C., Lindquist, E., Svensson, E. and Cambau, E. (2022). Diagnostic toolkit for tuberculosis: should we include urine lipoarabinomannan (LAM) detection in the WHO European Region? Clinical Microbiology and Infection, http://doi.org/10.1016/j.cmi.2022.06.022.
Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, T., Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N. and Robert, J. (2022). Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. Journal of Infection 85, 24–30, http://doi.org/10.1016/j.jinf.2022.05.017.
Maitre, T., Morel, F., Brossier, F., Sougakoff, W., Jaffre, J., Cheng, S., Veziris, N., Aubry, A. and on behalf of the NRC-MyRMA (2022). How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. Microorganisms 10, 1436, http://doi.org/10.3390/microorganisms10071436.
Eimer, J., Fréchet-Jachym, M., Le Dû, D., Caumes, E., El-Helali, N., Marigot-Outtandy, D., Mechai, F., Peytavin, G., Pourcher, V., Rioux, C., Yazdanpanah, Y., Robert, J., Guglielmetti, L. and for the LZDM group (2022). Increased linezolid plasma concentrations are associated with the development of severe toxicity in MDR-TB treatment. Clinical Infectious Diseases ciac485, http://doi.org/10.1093/cid/ciac485.
Bonnet, I., Haddad, E., Guglielmetti, L., Bémer, P., Bernard, L., Bourgoin, A., Brault, R., Catho, G., Caumes, E., Escaut, L., Fourniols, E., Fréchet-Jachym, M., Gaudart, A., Guillot, H., Lafon-Desmurs, B., Lanoix, J.-P., Lanotte, P., Lemaignen, A., Lemaire, B., Lemaitre, N., Michau, C., Morand, P., Mougari, F., Marigot-Outtandy, D., Patrat-Delon, S., Perpoint, T., Piau, C., Pourcher, V., Zarrouk, V., Zeller, V., Veziris, N., Jauréguiberry, S. and Aubry, A. (2022). Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms 10, 1215, http://doi.org/10.3390/microorganisms10061215.
Guglielmetti, L., Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia-Basteiro, A. L., Goletti, D., Jankovic, M., Kuksa, L., Maurer, F. P., Méchaï, F., Tiberi, S., Leth, F. van, Veziris, N. and Lange, C. (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00388-2022.
Le Ray, L. F., Aubry, A., Sougakoff, W., Revest, M., Robert, J., Bonnet, I., Veziris, N. and Morel, F. (2022). atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure. Emerg Infect Dis 28, 1062–1064, http://doi.org/10.3201/eid2805.212517.
Group, A. S. T., Georghiou, S. B., Rodwell, T. C., Korobitsyn, A., Abbadi, S. H., Ajbani, K., Alffenaar, J.-W., Alland, D., Alvarez, N., Andres, S., Ardizzoni, E., Aubry, A., Baldan, R., Ballif, M., Barilar, I., Böttger, E. C., Chakravorty, S., Claxton, P. M., Cirillo, D. M., Comas, I., Coulter, C., Denkinger, C. M., Derendinger, B., Desmond, E. P., Steenwinkel, J. E. M. de, Dheda, K., Diacon, A. H., Dolinger, D. L., Dooley, K. E., Egger, M., Ehsani, S., Farhat, M. R., Fattorini, L., Finci, I., Ray, L. F. L., Furió, V., Groenheit, R., Gumbo, T., Heysell, S. K., Hillemann, D., Hoffmann, H., Hsueh, P.-R., Hu, Y., Huang, H., Hussain, A., Ismail, F., Izumi, K., Jagielski, T., Johnson, J. L., Kambli, P., Kaniga, K., Karunaratne, G. H. R. E., Sharma, M. K., Keller, P. M., Kelly, E. C., Kholina, M., Kohli, M., Kranzer, K., Laurenson, I. F., Limberis, J., Lin, S.-Y. G., Liu, Y., López-Gavín, A., Lyander, A., Machado, D., Martinez, E., Masood, F., Mitarai, S., Mvelase, N. R., Niemann, S., Nikolayevskyy, V., Maurer, F. P., Merker, M., Miotto, P., Omar, S. V., Otto-Knapp, R., Palaci, M., Gutiérrez, J. J. P., Peacock, S. J., Peloquin, C. A., Perera, J., Pierre-Audigier, C., Pholwat, S., Posey, J. E., Prammananan, T., Rigouts, L., Robledo, J., Rockwood, N., Rodrigues, C., Salfinger, M., Schechter, M. C., Seifert, M., Sengstake, S., Shinnick, T., Shubladze, N., Sintchenko, V., Sirgel, F., Somasundaram, S., Sterling, T. R., Spitaleri, A., Streicher, E., Supply, P., Svensson, E., Tagliani, E., Tahseen, S., Takaki, A., Theron, G., Torrea, G., Deun, A. V., Ingen, J. van, Rie, A. V., Soolingen, D. van, Jr, R. V., Venter, A., Veziris, N., Villellas, C., Viveiros, M., Warren, R., Wen, S., Werngren, J., Wilkinson, R. J., Yang, C., Yılmaz, F. F., Zhang, T., Zimenkov, D., Ismail, N., Köser, C. U. and Schön, T. (2022). Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00166-2022.
Tunesi, S., Dû, D. L., Gualano, G., Millet, J.-P., Skrahin, A., Bothamley, G., Casas, X., Goletti, D., Lange, C., Musso, M., Palmieri, F., Pourcher, V., Rioux, C., Skrahina, A., Veziris, N., Viatushka, D., Jachym-Fréchet, M. and Guglielmetti, L. (2022). Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. Journal of Infection, http://doi.org/10.1016/j.jinf.2022.03.004.
Migliori, G. B., Wu, S. J., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., Garcia-Basteiro, A. L., Cambau, E., Chaisson, R. E., Chee, C. B. E., Dalcolmo, M. P., Denholm, J. T., Erkens, C., Esposito, S., Farnia, P., Friedland, J. S., Graham, S., Hamada, Y., Harries, A. D., Kay, A. W., Kritski, A., Manga, S., Marais, B. J., Menzies, D., Ng, D., Petrone, L., Rendon, A., Silva, D. R., Schaaf, H. S., Skrahina, A., Sotgiu, G., Thwaites, G., Tiberi, S., Tukvadze, N., Zellweger, J.-P., D’Ambrosio, L., Centis, R. and Ong, C. W. M. (2022). Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 26, 190–205, http://doi.org/10.5588/ijtld.21.0753.
Guyeux, C., Senelle, G., Refrégier, G., Bretelle-Establet, F., Cambau, E. and Sola, C. (2022). Connection between two historical tuberculosis outbreak sites in Japan, Honshu, by a new ancestral Mycobacterium tuberculosis L2 sublineage. Epidemiology & Infection 150, http://doi.org/10.1017/S0950268822000048.
Nyang’wa, B. T., LaHood, A. N., Mitnick, C. D. and Guglielmetti, L. (2021). TB research requires strong protections, innovation, and increased funding in response to COVID-19. Trials 22, 1–3, http://doi.org/10.1186/s13063-021-05331-4.
Bonnet, I., Enouf, V., Morel, F., Ok, V., Jaffré, J., Jarlier, V., Aubry, A., Robert, J. and Sougakoff, W. (2021). A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Front Cell Infect Microbiol 11, 707244, http://doi.org/10.3389/fcimb.2021.707244.
Guglielmetti, L., Ardizzoni, E., Atger, M., Baudin, E., Berikova, E., Bonnet, M., Chang, E., Cloez, S., Coit, J. M., Cox, V., de Jong, B. C., Delifer, C., Do, J. M., Tozzi, D. D. S., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, A., Khan, U., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moschioni, M., O’Brien, K., Okunbor, O., Oyewusi, L., Panda, S., Patil, S. B., Phillips, P. P. J., Pichon, L., Rupasinghe, P., Rich, M. L., Saluhuddin, N., Seung, K. J., Tamirat, M., Trippa, L., Cellamare, M., Velásquez, G. E., Wasserman, S., Zimetbaum, P. J., Varaine, F. and Mitnick, C. D. (2021). Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials 22, 651, http://doi.org/10.1186/s13063-021-05491-3.
Roelens, M., Battista Migliori, G., Rozanova, L., Estill, J., Campbell, J. R., Cegielski, J. P., Tiberi, S., Palmero, D., Fox, G. J., Guglielmetti, L., Sotgiu, G., Brust, J. C. M., Bang, D., Lienhardt, C., Lange, C., Menzies, D., Keiser, O. and Raviglione, M. (2021). Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med 204, 713–722, http://doi.org/10.1164/rccm.202009-3527OC.
Veziris, N., Bonnet, I., Morel, F., Guglielmetti, L., Maitre, T., Ray, L. F. L., Sougakoff, W., Robert, J. and Aubry, A. (2021). Impact of the revised definition of extensively drug-resistant tuberculosis. European Respiratory Journal 58, http://doi.org/10.1183/13993003.00641-2021.
Starshinova, A., Guglielmetti, L., Rzhepishevska, O., Ekaterincheva, O., Zinchenko, Yu. and Kudlay, D. (2021). Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical case). J Clin Tuberc Other Mycobact Dis 24, 100259, http://doi.org/10.1016/j.jctube.2021.100259.
Ok, V., Aubry, A., Morel, F., Bonnet, I., Robert, J. and Sougakoff, W. (2021). Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITe MGB® Assay. Antibiotics 10, 797, http://doi.org/10.3390/antibiotics10070797.
Hewison, C. and Guglielmetti, L. (2021). Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualised monitoring. Lancet Infect Dis 21, 894–895, http://doi.org/10.1016/S1473-3099(20)30836-7.
Guglielmetti, L. and Varaine, F. (2021). The coming-of-age of bedaquiline: a tale with an open ending. European Respiratory Journal 57, http://doi.org/10.1183/13993003.00066-2021.
World Health Organisation (2021). Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine), WHO, Geneva, URL: https://www.who.int/publications/i/item/technical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-(rifampicin-rifabutin-and-rifapentine) [Accessed March 2022].
Maitre, T., Guglielmetti, L. and Veziris, N. (2021). Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies. European Respiratory Journal 57, http://doi.org/10.1183/13993003.04315-2020.
Mohamed, S., Köser, C. U., Salfinger, M., Sougakoff, W. and Heysell, S. K. (2021). Targeted next-generation sequencing: a Swiss army knife for mycobacterial diagnostics? European Respiratory Journal 57, http://doi.org/10.1183/13993003.04077-2020.
Schön, T., Werngren, J., Machado, D., Borroni, E., Wijkander, M., Lina, G., Mouton, J., Matuschek, E., Kahlmeter, G., Giske, C., Santin, M., Cirillo, D. M., Viveiros, M. and Cambau, E. (2021). Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. Clinical Microbiology and Infection 27, 288.e1-288.e4, http://doi.org/10.1016/j.cmi.2020.10.019.